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Abstract 
 
Previously published work by our lab evaluating injury-induced changes in sensory 
neuron protein expression identified substantially increased levels of the neurosecretory 
protein VGF (non-acronymic), a neuropeptide precursor.  To further characterize the 
functional role of VGF-derived peptides in sensory neuron signaling and in the 
development of pain-relevant behavior, we utilized animal models, behavior analyses, 
and complementary morphologic and molecular techniques to pursue two approaches: 
using adeno-associated virus (AAV) vectors to modulate VGF expression in primary 
afferent neurons, and exploring whether VGF up-regulation is limited to somatic pain.   
From this work, we learned intrasciatic administration of AAV5 vectors yields inefficient 
and variable transduction of sensory and motor neurons, reminiscent of the AAV8 
serotype.  Intrathecal administration of AAV5-VGF resulted in successful transduction of 
the choroid plexus but poor expression in dorsal root ganglion (DRG) sensory neurons.  
Unexpected DRG sensory neuron degeneration was observed following highly-efficient 
transduction of AAV9, warranting caution in future experiments utilizing this vector 
serotype.  Antibiotic-induced visceral hypersensitivity was associated with up-regulation 
of VGF and other nociceptive neuropeptides in sensory neurons of the sixth lumbar 
DRG.  However, contrary to expectations, referred cutaneous allodynia associated with 
antibiotic-induced visceral hypersensitivity was not readily detected using a non-invasive 
mechanical stimulation assay.  Collectively, these findings encourage a re-evaluation of 
the tools employed to modulate VGF expression in primary afferent neurons in vivo, 
support the investigation of this novel signaling system beyond models of nerve injury, 
and are presented such that they can be used as an aid in the design of future work. 
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The purpose of this research was to investigate the functional role of VGF-derived 
peptides in sensory neuron signaling and in the development of pain-relevant behavior.  
These hypothesis-driven projects utilized genetic models, behavior analyses, and 
complementary morphologic and molecular techniques to further characterize this novel 
signaling system.  
 
Neuropathic pain.  Pain is an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage (Loeser and Treede, 2008).  Neuropathic pain is a 
distinct, complex, and chronic pain state initiated by a primary lesion or disease affecting 
the somatosensory nervous system (Grubb, 2010).  This condition is estimated to affect 
2-3% of the population, with an estimated prevalence of 4 million adults, and accounts 
for 25-50% of all visits to pain clinics (Wallace, 2005; Gilron et al., 2006).  Etiologies of 
nervous system pathology are varied and include direct nerve and spinal cord trauma, 
viral infections including Herpes zoster, and metabolic derangements including diabetes 
mellitus.  While neuropathic pain may result from lesions to the peripheral nervous 
system, central nervous system, or both, peripheral somatic nerves are most commonly 
involved (Hayes et al., 2002; Irving, 2005).  Key symptoms are spontaneous burning or 
piercing pain, paradoxical sensory loss, and hypersensitivity, which may manifest as 
allodynia – pain evoked by innocuous stimuli such as light touch, hyperalgesia – 
exaggerated pain in response to noxious stimuli, and hyperpathia – explosive abnormal 
pain that persists beyond a stimulus (Kehlet et al., 2006). 
 
Despite being a common and severe condition, therapy is often unsatisfactory.  
Neuropathic pain is frequently resistant to available pharmacologic options, including 
over-the-counter analgesics and opioids.  The impact of this disabling condition on 
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patients can be devastating, with an increased prevalence of depression, anxiety, and 
sleep disorders; decreased quality of life; and impairment of daily living activities and 
work performance (Gilron et al., 2006; Haanpää and Treede, 2010).  The underlying 
pathophysiology of neuropathic pain is heterogeneous, complex, and incompletely 
understood.  A better mechanistic understanding of the development and maintenance 
of neuropathic pain will likely identify new therapeutic targets as well as potential 
biomarker candidates for improved diagnosis. 
 
Neurosecretory protein VGF.  Dorsal root ganglion (DRG) sensory neurons are the 
first relay for the transmission of pain signals from the periphery to the central nervous 
system.  Peripheral nerve injury induces changes in sensory neuron gene expression, 
resulting in alterations of neuron function.  These modifications may impact the 
excitability, responsiveness, transmission, or survival of sensory neurons, and may or 
may not be reversible (Kehlet et al., 2006).  Previously published work by our lab 
evaluating injury-induced changes in sensory neuron protein expression identified 
substantially increased levels of the neurosecretory protein VGF (non-acronymic), a 
neuropeptide precursor (Riedl et al., 2009).  The nerve growth factor responsive Vgf 
gene is expressed in neurons within the central and peripheral nervous system and in 
various endocrine cells.  The encoded 617 amino acid protein is cleaved into a number 
of peptides, including several bioactive peptides from the highly conserved C-terminal 
region (Figure 1-1; Bartolomucci et al., 2011). 
 
In addition to rapid, robust, and persistent expression of VGF in injured sensory neurons, 
acute intrathecal administration of bioactive peptides derived from the C-terminal region 
of VGF to naïve animals resulted in thermal hyperalgesia and microglial p38 activation.  
	   4 
These and the findings of others have suggested that the VGF C-terminal peptides likely 
play an important functional role in neuronal signaling at the onset of nerve injury, 
mediating interactions between sensory neurons and spinal neurons or microglia (Moss 
et al., 2008; Riedl et al., 2009).  
 
To further characterize this novel signaling system, we questioned whether VGF 
overexpression in somatic sensory neurons would be sufficient to induce pain-related 
behavior (Chapter 2).  Conjointly, we investigated whether VGF upregulation was 
evident in sensory neurons in a model of visceral hypersensitivity, which also served to 
complement and inform other ongoing research (Chapter 3).  Additionally, in the course 
of this work we identified and analyzed potential methodology process improvements 
(Chapter 4).    
 
Genetic manipulation of VGF.  A powerful tool for studying gene function in an intact 
animal is the use of targeted mutations to regulate expression levels of the gene 
product.  However, genetic manipulation of VGF in primary sensory neurons has faced 
certain challenges.  Although well-characterized, constitutive VGF knockout mice exhibit 
a wide range of abnormalities – such as reduced postnatal survival – that preclude their 
use in the study of neuropathic pain (Hahm et al, 1999).  The development of sensory 
neuron-specific knock-out or knock-in mouse lines has been hampered by the lack of a 
tissue-specific promoter.  The most promising candidate is the Advillin gene, which is 
expressed almost exclusively in peripheral sensory neurons (Hasegawa et al., 2007).  
Unfortunately, the particular sequence of the Advillin promoter has not yet been 
determined, and sensory neuron-specific transgenic mouse lines are not commercially 
available.  
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A more tenable technique to manipulate gene expression in primary afferent neurons is 
to utilize viral-mediated gene transfer.  Recombinant adeno-associated virus (AAV) 
vectors have emerged as powerful vehicles for genetic manipulation of primary sensory 
neurons, mediating efficient, stable, and nontoxic transduction (Daya and Berns, 2008; 
Schultz and Chamberlain, 2008).  AAV are non-pathogenic, single-stranded DNA viruses 
in the Dependovirus genus of the Parvoviridae family.  The “gutless” recombinant 
vectors are devoid of viral genes (retaining only the inverted terminal repeats), can target 
non-dividing cells in vivo, and drive long-term expression of the transgene (Beutler and 
Reinhardt, 2009).  While the small packaging capacity of around 4400 bp for regulatory 
elements and the transgene can be a detriment, the capacity is sufficient to 
accommodate the encoding sequence for VGF (~ 1850 bp) and a standard ubiquitous 
promoter.  Sensory neuronal tropism has been demonstrated for multiple capsid 
serotypes of AAV, including AAV1 (Hollis et al., 2008; Homs et al., 2011); AAV2 (Boulis 
et al., 2003; Xu et al., 2003; Gu et al., 2005; Homs et al., 2011); AAV5 (Mason et al., 
2010; Vulchanova et al., 2010; Xu et al., 2012); AAV6 (Towne et al., 2009); AAV8 
(Vulchanova et al., 2010); and AAVrh20 (Pleticha et al., 2014b).  Not all sensory neuron 
subpopulations were equally targeted by each serotype, suggesting differential tropism 
based on the protein structure of the capsid.    
 
Viral access to primary afferent neurons is typically achieved through intrathecal, 
intraneural, or direct ganglionic injection.  Intrathecal administration by acute lumbar 
puncture presents less risk of direct traumatic damage to nervous tissue, but provides 
the vector access to spinal and supraspinal structures via the cerebrospinal fluid (Hylden 
and Wilcox, 1980).  Unintentional contamination of the cerebrospinal fluid has also been 
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observed following intraganglionic injection (Mason et al., 2010).  The neurotropism of 
AAV vectors is not limited to sensory neurons, and genetic manipulation of VGF in these 
off-target sites could complicate and confound the interpretation of behavioral analysis, 
particularly as VGF within the central nervous system has been implicated in mood and 
antidepressant responses (Hunsberger et al., 2007).  Identifying a route of administration 
that would sequester the vector to the region of interest is an important step in 
investigating the utility of viral-mediated gene transfer to further characterize the VGF 
signaling system in sensory neurons.   
 
Visceral pain.  Visceral pain, pain sensed as arising from the internal organs of the 
body, affects up to 25% of the population at any one time and is a prominent symptom of 
many clinical conditions (Moloney et al., 2015).  The neurobiological mechanisms of 
visceral pain differ from those involved in somatic pain, and clinically, visceral pain is 
characterized by diffuse and poorly localized pain that may be associated with referred 
pain to a somatic structure (Cervero and Laird, 1999).  Treatment is often insufficient 
and unsatisfactory.  Much like neuropathic pain, enhanced understanding of the 
underlying mechanisms of visceral pain is needed to aid in the development of novel 
therapeutics. 
 
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder, 
with key symptoms including abdominal pain or discomfort and altered lower bowel 
function (Sayuk and Gyawali, 2015).  The prevalence is estimated to be 10-15% in 
Western countries, although as few as 25% of IBS sufferers actually seek professional 
care (Hungin et al., 2005).  The multifactorial pathogenesis of IBS is incompletely 
understood, but involves psychosocial factors, altered signaling between the gut and 
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brain, alterations in the normal composition of the gut commensal microbiota, and low-
grade intestinal immune activation (Aguilera et al., 2015).  Inspired by the work of Verdú 
and colleagues (2006) describing the development of a murine visceral (colonic) 
hypersensitivity model by deliberate antibiotic-induced perturbation of the gut microflora, 
our laboratory sought to replicate this model principally to investigate mucosal 
neuroimmune interactions in the face of intestinal dysbiosis.  While the scope of this 
companion project goes beyond the work reported here, access to these mice provided 
a unique opportunity to examine sensory neurons innervating the gut for potential 
changes in VGF expression. 
 
OBJECTIVES 
 
The first series of experiments presented in Chapter 2 investigated the transduction 
efficiency of an AAV serotype 5 (AAV5) vector driving overexpression of VGF in lumbar 
DRG sensory neurons.  Through our collaborators, we received an AAV5 vector 
containing the rodent VGF sequence.  We expected that viral-mediated overexpression 
of VGF in primary afferent neurons would induce behavioral hypersensitivity.  Previous 
work in our lab had demonstrated sensory neuron tropism of AAV5 following intrathecal 
injection (Vulchanova et al., 2010).  However, we sought to avoid promiscuous 
transduction of distant, off-target sites following biodistribution by the cerebrospinal fluid.  
We questioned whether direct injection of AAV5 into the peripheral nerve would mediate 
efficient retrograde gene transfer limited to sensory neurons of the lumbar DRG.  
Following the initial experimental work in rats, we performed a pilot study using 
transgenic mice to better visualize the vector distribution and viral-mediated 
overexpression of rodent VGF following intrathecal administration.  
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In the latter section of Chapter 2, we report an unexpected sensory neuronopathy 
associated with AAV serotype 9 (AAV9)-mediated expression of green fluorescent 
protein.  These findings raised some concerns regarding the use of this AAV serotype in 
the DRG, particularly as random sensory neuron loss may complicate data interpretation 
in studies investigating sensory neuron signaling. 
 
The series of experiments presented in Chapter 3 investigated the behavioral phenotype 
and changes in sensory neuron protein expression associated with a murine model of 
antibiotic-induced dysbiosis.  We questioned whether intestinal dysbiosis and 
subsequent visceral hypersensitivity could be monitored non-invasively through 
evaluation of referred cutaneous allodynia.  In addition, we expected visceral 
hypersensitivity to be associated with upregulation of nociceptive neuropeptides 
including VGF. 
 
In Chapter 4, the method developed during the course of this work to clarify the positive 
cutoff values for immunofluorescence images of sensory neurons is discussed in detail.  
Finally, a time-saving modification to the common up-down method for assessing 
mechanosensitivity in rodents was recently published.  The original up-down method 
was utilized extensively in the experiments in Chapter 2.  We questioned the reliability of 
the recently proposed method for mechanosensitivity measurements in rodents and 
provide critical analysis of the limitations of this proposed testing method.   
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1, Schematic representation of the VGF C-terminal peptides.  By convention, 
VGF-derived peptides are designated by their four N-terminal amino acids and total 
length.  Bioactive peptides include TLQP-62, which contains TLQP-21 and AQEE-30. 
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Chapter 2 
 
 
Viral-mediated gene transfer to sensory neurons 
 
 
2.1  AAV5-mediated protein overexpression in sensory neurons following intrasciatic 
delivery in rats 
 
2.2 AAV5-mediated protein overexpression in sensory neurons following intrathecal 
delivery in transgenic mice 
 
2.3 Unexpected sensory neuronopathy following AAV9-mediated gene transfer 
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Portions of the work described in this chapter were included in the following: 
 
Dykstra JA, Schuster DJ, Riedl MS, Kitto KF, Fairbanks CA, Vulchanova L.  Unexpected 
sensory neuronopathy following adeno-associated virus mediated gene transfer.  Poster 
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Pride Research Day; Oct 2, 2013; Saint Paul, MN. 
 
Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, Elde R, Fairbanks 
CA, Vulchanova L.  Biodistribution of adeno-associated virus serotype 9 after intrathecal 
and intravenous delivery in the mouse.  Front Neurosci.  Special research topic on 
neuroanatomy, invited peer-reviewed contribution.  2014 Jun; 8:42. 
 
Dykstra JA, Riedl MS, Kitto KF, Lin W, Salton S, Fairbanks CA, Vulchanova L.  Gene 
transfer mediated by sciatic nerve delivery of AAV5-GFP and AAV5-VGF vectors.  
Poster session presented at: Neuroscience 2014.  44th Annual Meeting of the Society 
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SUMMARY 
 
Adeno-associated virus (AAV) vectors have emerged as powerful vehicles for genetic 
manipulation of primary sensory neurons, mediating efficient, stable, and nontoxic 
transduction.  Differential targeting of subtypes of dorsal root ganglia neurons by AAV5 
and AAV8 following intrathecal delivery by direct lumbar puncture has been 
demonstrated.  To determine whether increased expression of VGF in dorsal root 
ganglion (DRG) neurons is sufficient for induction of hypersensitivity, we sought to 
overexpress VGF using an AAV-mediated approach.  From this work, we learned 
intrasciatic administration of AAV5 vectors yields inefficient and variable transduction of 
sensory and motor neurons, reminiscent of the AAV8 serotype.  Intrathecal 
administration of AAV5-VGF resulted in successful transduction of the choroid plexus 
but poor expression in DRG sensory neurons.  A distinct behavioral phenotype was not 
evident in vector-treated rats or mice; however, this lack of desired biological effect is 
consistent with the absence of detectable transgene overexpression within neurons.  It is 
not clear whether the apparent paucity of neurotropism by AAV5-VGF is a consequence 
of poor transduction, low transgene expression, or failure of the transgene to yield 
bioactive peptides.  Finally, unexpected DRG sensory neuron degeneration was 
observed following highly efficient transduction of AAV9, warranting caution in future 
experiments utilizing this vector serotype.   
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INTRODUCTION 
 
VGF is endogenously expressed in sensory neurons, and is rapidly and robustly 
upregulated following peripheral inflammation and nerve injury (Moss et al., 2008; Riedl 
et al., 2009).  Several bioactive VGF-derived peptides from the C-terminus and adjacent 
region have acute pronociceptive effects when administered intrathecally, including 
TLQP-62 (Moss et al., 2008), AQEE-30 (Riedl et al., 2009), and TLQP-21 (Fairbanks et 
al., 2014).  However, the precise role played by VGF-derived peptides in the peripheral 
nervous system remains unclear.   
 
We hypothesized that VGF activity in sensory neurons modulates nociception and 
hypersensitivity in rodents, as measured by assays of pain-relevant behavior.  Studying 
the response of sensory neurons in the absence of VGF function has been hampered by 
the unavailability of a serviceable constitutive or conditional knock-out model.  
Pharmacologic blockade has also been hindered by the lack of a known endogenous 
protein receptor, with a receptor for just one of the peptides (TLQP-21) described only 
recently (Hannedouche et al., 2013).  To further understand the role played by VGF in 
nociception, rather than ablate VGF, we opted to overexpress VGF in primary afferent 
DRG neurons using viral-mediated gene transfer.  We expected prolonged endogenous 
expression of VGF would manifest as pain-related behavior, with a similar facilitatory 
role as exogenous peptide administered intrathecally. 
 
2.1.1  AAV5-MEDIATED PROTEIN OVEREXPRESSION IN SENSORY NEURONS 
FOLLOWING INTRASCIATIC DELIVERY IN RATS 
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Viral access to primary afferent neurons is typically achieved through injection into the 
cerebrospinal fluid or directly into the peripheral nervous tissue.  However, access of the 
vector to the cerebrospinal fluid allows potential transduction and viral-mediated gene 
transfer to supraspinal structures.  VGF is also endogenously expressed by neurons 
within the central nervous system, and overexpression in these off-target sites could 
complicate and confound the interpretation of behavioral analysis.  We questioned 
whether neuronal transduction by AAV5 could be confined to our region of interest by 
injecting the vector into the peripheral nerve.  Several AAV serotypes have been 
demonstrated as capable of transducing sensory or motor neurons following intrasciatic 
administration in rodent models, including AAV6 (Towne et al., 2009); AAV2 (Boulis et 
al., 2003; Xu et al., 2003; Gu et al., 2005; Homs et al., 2011); AAV1 (Hollis et al., 2008; 
Homs et al., 2011); and AAVrh20 (Pleticha et al., 2014b).  To our knowledge, there are 
no reports on the tropism and efficacy of AAV5 administered intraneurally.   
 
We investigated if direct injection of AAV5 into the sciatic nerve would mediate efficient 
retrograde gene transfer to sensory neurons of the lumbar DRG while reducing the 
likelihood of promiscuous transduction of distant, off-target sites.  Simultaneously, we 
tested whether viral-mediated overexpression of VGF in sensory neurons would induce 
behavioral hypersensitivity. 
 
2.1.2 METHODS 
 
Animals.  The experimental procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota.  Male Sprague-Dawley 
rats (200–250g; Harlan Labs, Madison, Wisconsin USA) were maintained in a specific 
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pathogen free vivarium with a 12:12 light/dark cycle (lights on at 07:00 h) and ambient 
temperature of 21±2°C.  The animals were housed in groups of 2–3 in transparent 
plastic cages with corncob bedding, paper nesting material, and ad libitum access to 
water and standard rodent chow.  The rats were allowed to habituate for at least 4 days 
under these conditions before intraneural injection.  Two separate experiments with 
groups of 4–10 rats were performed. 
 
AAV vector.  AAV5 containing a chicken β-actin promoter (CBA)-regulated rodent VGF 
sequence was produced by the University of North Carolina Vector Core (Chapel Hill, 
North Carolina USA) and was kindly provided by Dr. Stephen Salton (Icahn School of 
Medicine at Mount Sinai, New York, New York USA).  AAV5-CBA-GFP was purchased 
from the University of North Carolina Vector Core (AAV5.ss.PEM.BOL.CBA.GFP).    
 
Vector administration.  Animals were randomly divided into control and experimental 
groups.  Under isoflurane anesthesia, the left sciatic nerve was aseptically exposed at 
the mid-thigh level.  The nerve was elevated slightly to allow a thin strip of parafilm (~10 
mm wide) to be gently threaded underneath to provide support.  Five microliters of 
vehicle (sterile saline) or suspended viral vector were injected slowly into the left sciatic 
nerve using a 26G needle and a Hamilton syringe.  For both AAV5-GFP and AAV5-VGF, 
the construct solution contained 8 x 1012 viral vector genomes per milliliter.  The injection 
site was estimated to be proximal to the branching of the sural, peroneal, and tibial 
nerves; however, there is anatomical variability in the specific location of this branching, 
and the possibility of inadvertent injection into one of the branches could not be 
excluded.  Following intraneural injection, the overlying muscles were apposed and the 
skin was closed with surgical wound clips. 
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Behavioral analysis.  Rats were serially evaluated for vector-induced changes in 
mechanical and thermal sensitivity.  All rats were allowed to acclimate to the testing 
room environment in their home cages for at least 60 min prior to testing.  Behavior 
analysis occurred between 09:00 and 17:00 h and was performed by an investigator 
blinded to treatment groups.  Pain-relevant behavior was investigated two times prior to 
the injections.  Values from the second test day were used as the baseline.   
 
Mechanical sensitivity was assessed in rats using calibrated von Frey filaments 
(Stoelting Co., Wood Dale, Illinois USA) and the up-down method as adapted for rodents 
(Chaplan et al., 1994).  The rats were placed in individual plastic cages on a wire mesh 
platform and allowed at least 15 minutes to acclimate to the experimental setup.  A 
series of eight von Frey filaments (0.4–15 g, corresponding filament numbers 3.61–5.18) 
with logarithmically incremental stiffness were utilized, and testing was initiated with the 
middle filament (2.0 g, filament number 4.31).  The filament was applied vertically to the 
mid-plantar surface of the hind paw, avoiding the footpads, to the point of bending for 4 
sec.  A positive response was noted with brisk withdrawal or paw flinching.  Paw 
withdrawals due to locomotion or weight shifting were not counted and the trials were 
repeated.  Following a positive response, the next weakest stimulus was applied, and 
the next strongest stimulus was applied following a negative response.  An interval of at 
least 30 seconds was provided between stimuli.  The resulting pattern of positive and 
negative responses was used to calculate the 50% paw withdrawal threshold (PWT).   
 
Thermal hyperalgesia was investigated by the Hargreaves method (IITC Life Science, 
Inc., Woodland Hills, California USA).  The rats were placed in acrylic enclosures on a 
heated glass base maintained at 33–34°C and allowed to acclimate for approximately 10 
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minutes.  A focused, radiant light heat source was directed to the plantar surface and the 
time to paw withdrawal was recorded.  As before, paw withdrawals due to locomotion or 
weight shifting were not counted.  A cut-off of 25 sec was applied to avoid tissue 
damage.  An interval of at least 5 minutes was provided between stimuli.  The means of 
three tests were calculated and used as the withdrawal threshold to heat. 
 
The acetone drop test was used to assess cold allodynia.  Similar to von Frey testing, 
the rats were placed in individual cages on a wire mesh floor.  Using a syringe with a 
blunt needle tip, a drop (30 µL) of acetone was carefully applied to the plantar surface of 
the hind paw, avoiding any tactile contact, and the animal was observed for acetone-
evoked behaviors including elevation of the paw, flinching, and licking.  The total time 
spent in these evoked behaviors over a 1-minute observation period was recorded.  An 
interval of at least 5 minutes was provided between stimuli, and the mean of two tests 
was recorded for each hind paw. 
 
Tissue preparation.  Animals were terminally anesthetized (intramuscular injection of 
75 mg/kg ketamine, 5 mg/kg xylazine, and 1 mg/kg acepromazine) and sacrificed by 
transcardial perfusion with a pre-wash of calcium-free Tyrode’s (in mM: 116 NaCl, 5.4 
KCl, 1.6 MgCl2•6H2O, 0.4 MgSO4•7H2O, 1.4 NaH2PO4, 5.6 glucose, and 26 Na2HCO3), 
followed by modified Zamboni’s fixative (4% paraformaldehyde and 0.2% picric acid in 
0.1 M phosphate buffer, pH 6.9), and finally 10% sucrose in phosphate-buffered saline 
(PBS).  Brain, spinal cord, lumbar dorsal root ganglia (DRG), sciatic nerves, and liver 
were collected and incubated in 10% sucrose overnight at 4°C.  Tissues were 
cryosectioned (14 µm) and thaw-mounted onto gelatin-coated slides.  For fresh tissue 
collection, animals were anesthetized as above and sacrificed by exsanguination and 
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thoracotomy.  Harvested tissues were snap-frozen in liquid nitrogen and stored at -80°C.  
Sciatic nerves were immersed in fixative for two hours, then transferred to 10% sucrose 
overnight at 4°C.     
 
Immunohistochemistry.  Tissue sections were incubated in blocking buffer (PBS 
containing 0.3% Triton X-100, 1% bovine serum albumin, and 1% normal donkey serum) 
at room temperature for 30 min, then incubated overnight at 4°C in primary antisera 
prepared using blocking buffer as diluent.  Primary antisera used were: chicken anti-
GFP, 1:1000 (ab13870; Abcam, Cambridge, Massachusetts USA), protein A-purified 
guinea pig anti-VGF, 1:1000 (anti-AQEE-30, generated in our laboratory; Riedl et al., 
2009), rabbit anti-calcitonin gene related peptide (CGRP), 1:1000 (24112; ImmunoStar, 
Hudson, Wisconsin USA), and mouse anti-myelin basic protein (MBP), 1:1000 
(Chemicon MAB387; EMD Millipore, Darmstadt, Germany).  After rinsing with PBS, 
sections were incubated with appropriate combinations of cyanine-dye conjugated 
secondary antisera (Jackson ImmunoResearch, West Grove, Pennsylvania USA) for 
one hour at room temperature.  Sections were rinsed again in PBS and coverslipped 
using glycerol and PBS containing 0.1% p-phenylenediamine (Sigma Chemical Co., St. 
Louis, Missouri USA).  DRG sections were also incubated with NeuroTrace® 435/355 
Blue (Molecular Probes, Inc., Eugene, Oregon USA) per manufacturer’s instructions.  
Images were collected using an Olympus FluoView1000 confocal imaging system, 
analyzed using ImageJ (National Institutes of Health), and processed for publication 
using Adobe Photoshop.   
 
Cell counting.  DRG were mounted and sectioned perpendicular to the nerve root axis.  
Five equally spaced sections from each DRG separated by a minimum distance of 266 
	   19 
µm were selected for image collection.  The region of interest for imaging was visualized 
on the NeuroTrace channel, and the entire neuron population was imaged as best 
possible with non-overlapping fields, resulting in a minimum of 7 images per animal.  
Neuron cell body size and intensity of fluorescence were analyzed in ImageJ, using the 
Nissl-like NeuroTrace labeling to manually outline cell margins.  Only cells with a visible 
nucleus were counted.     
 
Image analysis.  Semi-quantitative image analysis was conducted as described in detail 
in Chapter 4.  Briefly, quadruple-labeled fluorescent tissue sections were imaged to 
produce a separate 8-bit greyscale image for each color channel.  The red (cyanine-3), 
green (cyanine-2), and far-red (cyanine-5) channels were used for markers of 
experimental interest, while the blue channel was exclusively used for Nissl-like 
NeuroTrace labeling.  All images from a specific antibody marker and within a particular 
color channel were compiled into a stack in ImageJ.  The image stack was then 
binarized using the Auto Threshold ImageJ plugin (version 1.15, Landini G, 
fiji.sc/Auto_Threshold) using the stack histogram, which would include images from 
control and experimental animals.  Splitting the stack back into individual images, each 
binarized version was saved with the original greyscale images.   
 
For cell counting, images of the identical microscope field were compiled into stacks of 
seven images: greyscale blue, greyscale red, binarized red, greyscale green, binarized 
green, greyscale far-red, and binarized far-red.  Manual cell outlining was conducted in 
the blue (NeuroTrace) channel, and the mean grey value (MGV) and cross-sectional 
area were simultaneously measured for the outlined region of interest for all images in 
the stack.  A cell was considered negative for a particular marker if the mean grey value 
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of the binarized channel was 0 (all pixels black).  To determine which cells had sufficient 
fluorescent intensity to be considered positive, the average greyscale MGV for the 
negative population of cells was calculated.  The threshold to be considered positive was 
determined as 3 standard deviations above the average for the negative population. 
 
Statistical analysis.  Data were entered into a spreadsheet for analysis.  Statistical 
tests were performed using GraphPad Prism (version 5.0d, GraphPad Software, San 
Diego, California USA, www.graphpad.com).  Groups were compared by Student’s t-
test, one-way analysis of variance (ANOVA) with post-hoc Bonferroni’s multiple 
comparison test, or two-way repeated measures ANOVA with post-hoc Bonferroni’s 
multiple comparison test, where best applicable.  Data are expressed and plotted as 
mean ± SEM.  A p value of < 0.05 was considered significant. 
 
2.1.3 RESULTS 
 
Experiment 1.  Naïve rats were randomly divided into three treatment groups: 
intraneural injection of AAV5-VGF (n = 10), AAV5-GFP (n = 6), or saline (n = 4).  
Following injection, behavior testing was performed weekly for 6 weeks.  Both the 
ipsilateral (left, affected) and contralateral (right, naïve) hind paws were evaluated.  
Reliable behavior data could not be obtained on the 35-day post-injection time point due 
to adverse environmental conditions in the testing room beyond the experimenter’s 
control, for which that time point was omitted from analysis. 
 
Mechanical sensitivity thresholds of the ipsilateral hind paws in both vector-treated 
groups declined from baseline and trended lower than the saline-treated group by the 
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final measurement, but were not statistically different at any time point (Figure 2-1 A).  A 
similar non-significant decay in the PWT was observed in the contralateral hind paws of 
the vector-treated animals.  To reduce the repeated measures design into a single, 
representative value for each individual, the area under the PWT curve was calculated 
using the minimum possible threshold value for this filament series (3.39) as the floor 
value.  There was no significant difference in the average area under the curve between 
the saline-treated group and either vector group for each hind paw (Figure 2-1 B). 
 
Thermal sensitivity measurements included serial evaluation for heat hyperalgesia and 
one-time assessment of cold allodynia in lieu of Hargreaves testing on the final behavior 
testing time point.  No significant changes in paw withdrawal from radiant heat were 
observed for either vector-treated group (Figure 2-1 C).  Acetone-evoked behaviors were 
limited to flinching or licking immediately after drop application; no prolonged behaviors 
consistent with cold allodynia were observed (data not shown). 
 
Successful AAV5-mediated transfer of GFP or VGF could not be determined until the 
tissues were evaluated by immunohistochemistry.  An animal was considered to be 
positive if AAV5-driven immunoreactivity (-ir) was detectable within the sciatic nerve near 
or proximal to the injection site, within the associated DRG, or within the spinal cord or 
supraspinal structures.  However, vector-mediated expression of VGF could not be 
discriminated immunohistochemically from endogenous protein in the DRG or spinal 
cord.  Given that GFP labeling in the DRG or spinal cord was only evident in animals 
that also showed GFP-ir within the sciatic nerve, and that endogenous VGF-ir in the 
sciatic nerve was negligible, we utilized the presence or absence of VGF-ir within the 
injected sciatic nerve to determine if successful transfer occurred.  Based on 
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immunohistochemistry of the left sciatic nerve, AAV5-mediated transfer was confirmed in 
3 of 6 animals for GFP and in 5 of 10 animals for VGF.   
 
Behavior outcome measures were re-analyzed including only those subjects determined 
to be positive for vector transduction by immunohistochemistry.  In addition, one animal 
from the saline treatment group developed persistently reduced tactile thresholds in the 
right hind paw 7 days post-injection due to an unexplained injury, and was also 
excluded.  Intra- and inter-subject variability was more pronounced, owing in part to the 
smaller group sizes.  There was no significant difference in behavior outcomes in the 
vector-treated animals (Figure 2-2). 
   
Immunohistochemical analysis revealed AAV5-driven GFP-ir or VGF-ir predominantly in 
the sciatic nerve in the region of the injection site (Figure 2-3).  GFP-ir was widespread 
within non-neuronal elements.  Double-labeling with anti-MBP revealed bounding of 
myelin by GFP-positive cytoplasm, suggesting AAV5-GFP transduction of Schwann cells 
(Figure 2-3 A-D).  The vector-mediated expression of anti-VGF was less intense and 
multifocal, appearing more limited than in the animals with GFP-ir, but still in cells with 
MBP immunoreactivity (Figure 2-3 E-H). 
 
Semi-quantitative image analysis was performed on labeled sections from the ipsilateral 
fifth lumbar (L5) DRG (Figure 2-4).  The total number of neurons counted per animal was 
448 ± 17.5.  GFP-ir in sensory neurons was limited to two of the animals with positive 
expression in the sciatic nerves, and the transduction rate was low (1.2 and 1.5%).  Too 
few DRG neurons were positive for GFP to assess preferential transduction based on 
neuron size.  No difference was found in the sensory neuron expression of VGF 
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between treatment groups, and viral-mediated expression could not be distinguished 
from endogenous protein (Figure 2-4 M).  Similarly, no difference was found in the 
immunoreactivity to the nociceptive signaling neuropeptide CGRP between treatment 
groups (Figure 2-4 N). 
 
Limited GFP-ir was evident in the dorsal root and superficial laminae of the ipsilateral 
dorsal horn of the L5 region of the spinal cord (Figure 2-5 A).  Ventral horn motor 
neurons were also occasionally transduced (Figure 2-5 A, inset).  As in the DRG, viral-
mediated expression of VGF could not be distinguished from endogenous protein 
(Figure 2-5 C-D).  There was no evidence of viral-driven gene expression in the choroid 
plexus or brain.  Absence of GFP-ir or VGF-ir in the liver was consistent with a lack of 
systemic distribution. 
 
Thus, intraneural administration of AAV5 vectors resulted in poor and variable 
transduction efficiency of sensory neurons.  Viral transduction was confined to the 
peripheral nerve and its associated DRG and spinal cord segment; supraspinal 
structures were spared.  Vector-associated changes in hypersensitivity or sensory 
neuron neuropeptide expression were not evident.  However, the 50% success rate in 
viral transfer led to reduced group sizes for analysis. 
 
Experiment 2.  Naïve rats were randomly divided into two treatment groups: intraneural 
injection of AAV5-VGF (n = 12) or saline (n = 4).  Following injection, behavior testing 
was performed at 6-day intervals on both the ipsilateral (left, affected) and contralateral 
(right, naïve) hind paws.  Assays included serial assessment of tactile and cold 
allodynia.  Fresh DRG and spinal cord were collected and frozen for potential analysis.  
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Left sciatic nerves were immersion-fixed for immunohistochemical confirmation of AAV5-
VGF transduction.  Vector-mediated transfer to cellular elements in the sciatic nerve was 
confirmed by immunohistochemistry in 8 of 12 animals.  Analysis of the filament-based 
von Frey and acetone drop tests was performed including all animals (Figure 2-6) and 
including only individuals with evident transduction versus the saline-injected controls 
(Figure 2-7).  There was no evidence of a change of mechanical hypersensitivity over 
time in the vector-treated group.  Similarly, no further acetone-evoked behaviors were 
observed.                 
 
As in Experiment 1, intraneural administration of AAV5-VGF yielded no discernable 
changes in paw withdrawal thresholds from mechanical or cold stimuli.   
 
2.1.4 DISCUSSION 
 
To investigate our hypothesis that VGF activity in sensory neurons modulates 
nociception and hypersensitivity, we investigated the utility of intrasciatic injection to 
mediate retrograde viral-mediated gene transfer and protein overexpression in lumbar 
DRG sensory neurons.  AAV5-induced gene expression was observed within sensory 
and motor neurons contributing to the injected sciatic nerve; however, the overall 
transduction efficiency of nerve fibers was poor and variable.  Viral-driven gene 
expression predominated in putative Schwann cells in the vicinity of the injection site.  
There was no observed dissemination of the viral vector to contralateral DRG or spinal 
cord, supraspinal structures, or liver.  A change in mechanical sensitivity was 
inconsistently observed in vector-treated animals. 
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Differential tropism and cellular expression.  Sensory neuronal tropism of AAV5 has 
been previously described following intrathecal (Vulchanova et al., 2010; Xu et al., 2012) 
and direct ganglionic injection (Mason et al., 2010).  However, access of the vector to 
the cerebrospinal fluid by either of these methods, whether intentional or not, allows 
potential transduction and viral-mediated gene transfer to supraspinal structures.  
Protein overexpression in these off-target sites could complicate and confound the 
interpretation of behavioral analysis, particularly as VGF within the central nervous 
system has been implicated in mood and antidepressant responses (Hunsberger et al., 
2007).  We questioned whether neuronal transduction by AAV5 could be confined to our 
region of interest by changing the route of administration.  Several AAV serotypes have 
been demonstrated as capable of transducing sensory or motor neurons following 
intrasciatic administration in rodent models, including AAV6 (Towne et al., 2009); AAV2 
(Boulis et al., 2003; Xu et al., 2003; Gu et al., 2005; Homs et al., 2011); AAV1 (Hollis et 
al., 2008; Homs et al., 2011); and AAVrh20 (Pleticha et al., 2014b).  To our knowledge, 
there are no reports on the tropism and efficacy of AAV5 administered intraneurally.  
This prompted us to investigate AAV5 in this aspect. 
 
In our hands, intrasciatic administration of AAV5 resulted in preferential transduction of 
Schwann cells in the vicinity of the injection site.  The transduction pattern, including the 
apparent loss of neuronal tropism, closely resembles reports of the intrasciatic 
administration of AAV8 (Homs et al., 2011) and adenoviral vectors (Glatzel et al., 2000).  
While being mindful of interstudy variations in vector dose, viral titers, injection 
procedures, promoters, and transgenes, the results of these studies suggest the 
transduction efficacy and cellular tropism of AAV vectors following intraneural 
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administration are likely serotype-dependent.  We considered several potential causes 
for this change in viral transduction efficacy. 
 
Access to the target cells.  A potential hindrance to vector transduction is the connective 
tissue ensheathment of the peripheral nerve.  The perineurium consists of concentric 
layers of squamous perineurial cells alternating with layers of extracellular matrix, 
consisting of as many as 15 cellular lamellae in peripheral nerve trunks.  The tight 
junctions joining perineurial cells and the thickness of the basement membranes create 
a diffusion barrier.  Meanwhile, at the subarachnoid angle of the dorsal root where the 
meningeal coverings of the spinal cord merge with the peripheral nerve connective 
tissue ensheathments, the perineurial cells lack tight junctions (Mizisin and Weerasuriya, 
2011).  This discontinuity allows communication between the subarachnoid and 
intercellular spaces and permits easier penetration of substances within the 
cerebrospinal fluid to the dorsal root and proximal aspect of the DRG, as evidenced 
following intrathecal administration of fluorescein by Abram et al. (2006).  This anatomic 
access to axons in the dorsal root and cell bodies in the proximal ganglion likely explains 
the success of viral transduction of sensory neurons following intrathecal injection.  
Other serotypes of AAV seem to be more capable of traversing the diffusion barrier of 
the peripheral nerve trunk than AAV5.  However, the transduction of Schwann cells is 
evidence of at least some AAV5 viral particles successfully breaching the perineurium. 
 
Receptor-mediated endocytosis.  Another possible cause for the change in transduction 
efficacy may be a difference in the distribution of the AAV5 receptor between the cell 
soma and the peripheral axon.  Interestingly, platelet-derived growth factor (PDGF) 
receptor has been identified as a co-receptor for AAV5 (Di Pasquale et al., 2003).  
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PDGF receptor expression in the rat sciatic nerve and dorsal root ganglia is down-
regulated in maturity, but these receptors continue to be expressed at high levels in 
Schwann cells in adult animals (Eccleston et al., 1993). Neuronal tropism may not be 
lost but may be subject to greater competition from other cellular constituents of the 
nerve.  It seems possible that differences in the expression of these or other unidentified 
receptors at the injection site may be influencing the effective transduction of this AAV 
serotype.   
 
Access to the nucleus.  Following receptor-mediated endocytosis, the viral vector must 
be transported retrograde from the point of entry at the axon to the nucleus of the neuron 
before the viral genome can be expressed.  The mechanisms involved in intracellular 
processing of AAV are incompletely understood (Wu et al., 2006), and it is unknown if 
AAV5 exploits a different pathway than other AAV serotypes.  Impaired trafficking of 
AAV to the nucleus has been documented as an obstacle for AAV2 transduction in 
certain cell types (Hansen et al., 2000).  Inefficient retrograde trafficking of AAV5 to the 
cell soma would manifest as a failure of viral-mediated gene expression, even if the 
vector were able to bind and gain entry to the axon successfully.  Retrograde transport 
of AAV5 has been documented in the brain over distances as large as 6 mm, but was 
selective for certain subpopulations of neurons (Aschauer et al., 2013; Rothermel et al., 
2013).     
 
Viral-mediated gene expression.  The promoter driving expression of the experimental or 
reporter gene must be active in the targeted cell, and the cell must have the necessary 
machinery for post-translational modification of the mature protein.  Poor expression 
may result in underestimating the number of neurons or other cells targeted by AAV5.  
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The cytomegalovirus (CMV) early enhancer/promoter and the hybrid CMV 
enhancer/chicken β-actin (CBA) promoter are commonly used in AAV vectors and 
typically yield high, ubiquitous expression levels in various cell types (Gray et al., 
2011a).  However, the mechanisms by which VGF is cleaved and the resulting peptides 
are modified to become biologically active are not understood.  If the viral-driven 
exogenous protein is improperly processed intracellularly, it could result in a failure of 
immunohistochemical detection.   
 
Vector dosage.  Transduction efficacy may be partially compensated by changing the 
viral dosage.  We questioned how the dose used in our study would compare to those 
reported for the intrasciatic administration of other AAV serotypes.  Unfortunately, viral 
vector dose may be reported in two different ways.  The physical titer is strictly a 
measurement of the amount of virus present (viral particles or genome copies), while the 
functional titer is the measurement of infectious virus (transducing units).  Given the 
inability to extrapolate physical titers from functional titers and the lack of a functional 
titer for our vector, only those that reported physical titers were considered.  From the 
reports referenced above, intrasciatic delivery doses in rats ranged from 7.00 x 107 to 
1.20 x 1010 viral particles, and in mice was 1.80 x 109 viral particles, all of which were 
lower or fairly equivalent to our dose of 4.00 x 1010 viral particles.  However, this 
comparison may not be meaningful, as each titer is from a different AAV serotype.  The 
dose in this study may be below the minimum effective dose for neuronal transduction.  
The practicality of obtaining a functional titer for future work is also debatable, as in vitro 
infectivity assays do not necessarily predict in vivo performance.  
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Behavior assessment.  To assess the functional consequences of intrasciatic injection 
and viral-mediated gene transfer, rats injected with vector or vehicle were serially tested 
for tactile allodynia, thermal hyperalgesia, and/or cold allodynia in the plantar region of 
the hind paw.  A change in mechanical sensitivity was inconsistently observed in AAV5-
treated animals in the first experiment.  This finding was not repeated in the second 
experimental cohort.  While the group sizes in each experiment were decremented due 
to failure of viral-mediated gene transfer or other aberrations, the number of animals with 
confirmed vector transduction by immunohistochemistry slightly improved in the second 
experiment (n = 5 in the first, n = 8 in the second) and the number of saline-treated 
control animals were similar (n = 3 in the first, n = 4 in the second).  The cause of the 
mechanosensitivity threshold shift is not clear. 
 
An attractive explanation for the change in tactile sensitivity is a physiological response 
to the viral-driven gene product.  Intrathecal administration of exogenous VGF-derived 
peptides has been shown to induce mechanical and cold allodynia (Moss et al., 2008), 
as well as thermal hyperalgesia as determined by warm water immersion tail-withdrawal 
testing (Riedl et al., 2009; Fairbanks et al., 2014).  Viral-mediated overexpression of 
VGF within the somatosensory pathway may be sufficient to induce hypersensitivity, with 
the specific manifestation subject to the random pattern of transduction.  However, there 
are several concerns with this interpretation.  Sensory neuronal transduction could not 
be quantified for AAV5-VGF, but based on the transduction efficiency of GFP, it is likely 
that viral-mediated expression of VGF in sensory neurons is similarly low.  It seems 
unreasonable to suspect VGF overexpression in such a limited population of sensory 
neurons would be sufficient to manifest a change in tactile behavior.  On the other hand, 
transduction of Schwann cells in the vicinity of the injection site was evident.  Provided 
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these cells are capable of appropriate VGF processing, local release of VGF-peptides 
may mediate neuronal communication and signaling. 
 
Yet this putative regional, unilateral signaling process fails to explain the observed 
contralateral effect.  Mechanosensitivity thresholds tended to decrease in the naïve right 
hind paw in vector-treated animals comparable to the affected left hind paw.  No 
contralateral dissemination of the viral vector was evident by immunohistochemistry of 
the DRG or spinal cord.  To directly achieve this bilateral response, secreted viral-gene 
encoded product would have to gain access to either the cerebrospinal fluid or systemic 
circulation.  The cell body-rich regions of the DRG have increased vascular permeability 
(Hirakawa et al., 2004; Abram et al., 2006), so it may be possible for circulating VGF 
peptides to globally access other DRG.  However, to gain access to the bloodstream, 
viral-driven gene products released into the endoneurial space would still have to 
overcome the blood-nerve barrier.  The relatively impermeable perineurium and 
endoneurial capillaries tightly regulate entry into and exit from the endoneurial 
microenvironment (Weerasuriya and Mizisin, 2011).  It is not known if transport of VGF-
derived peptides across the blood-nerve barrier is a reasonable expectation. 
 
Another possible explanation for the observed variations in mechanosensitivity 
thresholds is damage to the nerve.  Exposure of the sciatic nerve trunk and application 
of the injection could potentially result in nerve injury-induced hypersensitivity.  If 
iatrogenic trauma was the sole cause of mechanosensitivity deviations, the effect should 
have been unilateral, equally possible in both vector-treated and vehicle-treated groups, 
and likely transient as hypersensitivity would resolve as regeneration occurred.  To more 
thoroughly assess the likelihood of nerve damage, semi-thin, transverse sections of the 
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nerve distal to the injection site could be analyzed for demyelination and Wallerian 
degeneration.  Damage to the neurons could also be caused by toxic effects secondary 
to the expression of transduced proteins.  Viral-mediated gene overexpression may have 
induced the death of sensory neurons or, as might be more likely in this case, Schwann 
cells.  Immunofluorescence is not ideal for scoring sciatic nerves for the presence of 
demyelination, digestion chambers, and axonal loss.  Semi-thin analysis may be 
warranted in future work to rule out neurotoxicity.  For a more thorough discussion of 
transduced proteins being associated with toxic effects, please see the section on 
sensory neuronopathy later in this chapter. 
 
None of these options satisfactorily explain why shifting of the mechanosensitivity 
thresholds was evident in the first experimental cohort – in vector-treated animals with 
and without positive immunoreactivity for the viral gene product – and was not evident in 
the similarly treated second experimental cohort.  Aside from randomness associated 
with viral vector transduction, we questioned if these experimental groups were different 
in another meaningful way.  This led us to recognize the change in behavior measures 
between cohorts.  Rats in the first experimental groups were serially tested for tactile 
allodynia and thermal hyperalgesia, while in the second cohort the thermal nociception 
test was replaced with the acetone drop test for cold allodynia.  Sensory thresholds were 
less stable in the rats evaluated for thermal nociception following von Frey testing.  None 
of the animals exhibited any signs of tissue injury or burns in the plantar region of either 
hind paw to help explain the change in tactile response.                       
 
All behavior evaluations were performed in an isolated designated testing room separate 
from the vivarium.  In part due to scheduling limitations for this shared research space, 
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the two respective tests were performed on the same day.  Despite the assays being in 
the same location and for similar lengths of time, the testing experience was not equal 
between the cohorts of rats.  In the first experiment, animals were transferred from the 
von Frey testing table directly to the Hargreaves apparatus without being returned 
temporarily to their respective home cages.  In the second experiment, assays were also 
conducted back-to-back, but both tests were conducted on the von Frey testing table 
and the stimuli were non-noxious.  Learning can be extremely rapid, and it is possible 
that the consistent sequence of testing or that non-nociceptive cues within the room, 
such as unfavorable visual, olfactory, or ultrasonic auditory signals between rats, 
conditioned individual animals into a state of anticipatory hypervigilance (Detloff et al., 
2010).  Meanwhile, the tests for allodynia in the second cohort did not seem to generate 
the same level of apprehension.   
 
Given the similar levels of threshold decay between the affected and unaffected limb in 
individual animals irrespective of treatment group or outcome, it seems likely that this 
effect is mediated more globally than by viral-induced protein expression in the vicinity of 
the left sciatic nerve.  The possibility exists that the behavior outcome measures are 
biased by learning and/or the psychological state of the animals.  As cautioned by Le 
Bars and colleagues in their review on animal models of nociception (2001) regarding 
mechanical sensitivity, “anticipatory or training phenomena are likely to blur the 
response, which consequently cannot be interpreted other than in terms of pain.”  The 
sensory threshold decay suggests the development of physiologic hypersensitivity, but 
may be artificially low due to psychological stress. 
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2.2.1  AAV5-MEDIATED PROTEIN OVEREXPRESSION IN SENSORY NEURONS 
FOLLOWING INTRATHECAL DELIVERY IN TRANSGENIC MICE 
 
Intrasciatic administration of AAV5 vectors yielded predominately local transduction with 
inefficient and variable transduction of sensory and motor neurons.  We concluded that 
peripheral nerve injection was not a viable strategy to limit VGF overexpression to 
lumbar DRG sensory neurons using an AAV5 vector. 
 
To further investigate the role played by VGF in sensory neurons, we performed a pilot 
study in mice administering the same vectors by direct lumbar puncture.  Based on 
previous work with this vector serotype and delivery method (Vulchanova et al., 2010), 
we expected viral transduction to be evident in the lumbar dorsal root ganglia and spinal 
cord as well as in off-target supraspinal regions.  As the overexpression of VGF should 
manifest through behavioral effects dependent on the region affected, we included 
behavior assessments of pain-related and depressive-like behaviors, given the 
antidepressant activity of VGF in the central nervous system (Hunsberger et al., 2007).    
 
A setback of the study in rats was the inability to discriminate endogenous and viral-
mediated VGF expression.  To better visualize the vector distribution and viral-mediated 
overexpression of rodent VGF, we used a humanized VGF-knock-in mouse line and 
antisera lacking cross-reactivity between species.  
 
2.2.2 METHODS 
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Animals.  The experimental procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota.  We utilized the 
B6;129Sv-Vgf tm(VGF)/J mouse line and B6;129Sv/J mice on the same genetic 
background lacking the targeted mutation (hereafter referred to as hVGF and mVGF, 
respectively).  In the hVGF mouse line, the coding sequence of mouse VGF1-617 is 
replaced by human VGF1-615, so that the human protein is expressed from this allele and 
the wild-type mouse protein is undetectable.  The mVGF mouse line expresses 
endogenous mouse VGF.  The generation of this humanized VGF-knock-in mouse line 
was recently described by the lab of origin (Fargali et al., 2014).  N2F1 breeders of each 
line, donated by Dr. Stephen Salton (Icahn School of Medicine at Mount Sinai, New 
York, New York USA), were intercrossed to yield homozygous N2F2 progeny and 
experiments were performed on these mixed-background offspring.  Experimental mice 
were maintained in a conventional vivarium with a 12:12 light/dark cycle (lights on at 
07:00 h) and ambient temperature of 21±2°C.  The animals were socially housed in 
groups of 4 in transparent plastic cages with corncob bedding, compact cotton nesting 
material, and ad libitum access to water and standard rodent chow.   
 
AAV vector.  AAV5 containing a chicken β-actin promoter (CBA)-regulated rodent VGF 
sequence was produced by the University of North Carolina Vector Core (Chapel Hill, 
North Carolina USA) and was kindly provided by Dr. Stephen Salton (Icahn School of 
Medicine at Mount Sinai, New York, New York USA).  AAV5-CBA-GFP was purchased 
from the University of North Carolina Vector Core (AAV5.ss.PEM.BOL.CBA.GFP).    
 
Vector administration.  Adult male hVGF mice (20–25g) were randomly divided into 
control and experimental groups.  Twenty minutes prior to vector injection, 200 µL of 
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25% mannitol solution was delivered via the tail vein to promote enhanced AAV vector 
transduction of primary sensory neurons (Vulchanova et al., 2010).  AAV vector 
constructs were delivered intrathecally by direct lumbar puncture in unanesthetized mice 
as described by Hylden and Wilcox (1980) with a minor modification.  To conserve viral 
vector, a length of PE10 tubing was connected between a 50 µL Luer-hub Hamilton 
syringe and a 30-gauge, 0.5 inch needle.  To administer the injection, the animal was 
gripped gently at the iliac crest and the needle was inserted, bevel side up, at an 
approximate 45° angle centered between the hipbones.  Puncture of the dura was 
indicated by a reflexive flick of the tail, and an injection volume of 10 µL of saline or 
vector construct solution was delivered intrathecally.  For both AAV5-GFP and AAV5-
VGF, the construct solution contained 8 x 1012 viral vector genomes per milliliter.  
Following the injection, the animals were returned to their home cages.   
 
Behavioral analysis.  Mechanical sensitivity and depression-like behavior were 
evaluated in hVGF mice treated with saline, AAV5-GFP, or AAV5-VGF, and in age-
matched male mVGF mice with no experimental manipulations (naïve).  Mechanical 
responses were serially assessed using an electronic von Frey aesthesiometer (IITC Inc. 
Life Sciences, Woodland Hills, California USA) by an investigator blinded to treatment 
groups.  Mice were placed in individual glass enclosures on a wire mesh platform and 
allowed to acclimate for 15 to 30 minutes.  The probe was applied to the plantar surface 
of the hind paw until a brisk withdrawal response terminated application of pressure, 
which was recorded by the instrument.  The mean of three tests was calculated for each 
hind paw. 
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Tail suspension was used to assess depression-like behavior in response to a short-
term, inescapable stress.  Mice were allowed to acclimate to the experimental room for 
at least 40 minutes prior to the assay.  Immediately before the test, a short length of 
white artist tape was applied perpendicular to the tail approximately 1 cm from the tail 
base.  The free ends of the tape were flattened together and a hole was punched 
through the double-layered tape.  The tail suspension apparatus consisted of a plastic 
box enclosure with a central ceiling suspension hook and three opaque white walls to 
contrast with the coat color of the mice.  Each mouse was suspended on the hook 
through the hole in the adhesive tape, facing downward and at least 15 cm away from 
the surface of the walls or floor.  Behavior was video-recorded for 180 seconds.  
Afterwards, the tape securement was carefully removed from the suspension hook, the 
adhesive tape was gently separated to liberate the tail, and the mouse was returned to 
the home cage.  During the test, experimenters refrained from making noise, movement, 
or visual contact to minimize any effects of their presence on animal behavior.  Subjects 
were monitored throughout the test via a rotatable recording screen to ensure the 
suspension was secure.  After each testing session, the equipment was cleaned with 
ethanol solution to eliminate olfactory cues.  The video recordings were indexed, edited 
to remove subject identification cards recorded before each test, and randomized.  An 
investigator blinded to the treatment groups manually recorded the amount of time 
individual mice spent immobile.  Immobility scores were calculated for the entire duration 
of the test. 
 
Tissue preparation.  Animals were terminally anesthetized with isoflurane and 
sacrificed by transcardial perfusion with a pre-wash of calcium-free Tyrode’s (in mM: 116 
NaCl, 5.4 KCl, 1.6 MgCl2•6H2O, 0.4 MgSO4•7H2O, 1.4 NaH2PO4, 5.6 glucose, and 26 
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Na2HCO3), followed by modified Zamboni’s fixative (4% paraformaldehyde and 0.2% 
picric acid in 0.1 M phosphate buffer, pH 6.9), and finally 10% sucrose in phosphate-
buffered saline (PBS).  Brain, spinal cord, lumbar dorsal root ganglia (DRG), and liver 
were collected and incubated in 10% sucrose overnight at 4°C.  Tissues were 
cryosectioned (14 µm) and thaw-mounted onto gelatin-coated slides. 
 
Immunohistochemistry.  Tissue sections were incubated in blocking buffer (PBS 
containing 0.3% Triton X-100, 1% bovine serum albumin, and 1% normal donkey serum) 
at room temperature for 30 min, then incubated overnight at 4°C in primary antisera 
prepared using blocking buffer as diluent.  Primary antisera used were chicken anti-GFP, 
1:1000 (ab13870; Abcam, Cambridge, Massachusetts USA) and rabbit anti-TLQP-21, 
1:1000 (generated in our laboratory; Possenti et al., 2012; Fairbanks et al., 2014).  After 
rinsing with PBS, sections were incubated with appropriate combinations of cyanine-dye 
conjugated secondary antisera (Jackson ImmunoResearch, West Grove, Pennsylvania 
USA) for one hour at room temperature.  Sections were rinsed again in PBS and 
coverslipped using glycerol and PBS containing 0.1% p-phenylenediamine (Sigma 
Chemical Co., St. Louis, Missouri USA). 
 
Statistical analysis.  Data were entered into a spreadsheet for analysis.  Statistical 
tests were performed using GraphPad Prism (version 5.0d, GraphPad Software, San 
Diego, California USA, www.graphpad.com).  Groups were compared by Student’s t-
test, one-way analysis of variance (ANOVA) with post-hoc Bonferroni’s multiple 
comparison test, or two-way repeated measures ANOVA with post-hoc Bonferroni’s 
multiple comparison test, where best applicable.  Data are expressed and plotted as 
mean ± SEM.  A p value of < 0.05 was considered significant. 
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2.2.3 RESULTS 
 
Naïve hVGF mice were randomly divided into three treatment groups: intrathecal 
injection of AAV5-VGF (n = 7), AAV5-GFP (n = 6), or saline (n = 9).  An additional group 
of naïve mVGF mice (n = 8) received no injections.  One animal in the AAV5-GFP group 
was diagnosed with a spontaneous unrelated disease condition (metastatic thymic 
lymphosarcoma) late in the course of the study.  The euthanasia of this animal preceded 
the remainder of the cohort by less than one week.  The tissues were still utilized for 
immunohistochemical screening.  However, due to the unknown influence of the 
spontaneous disease condition, behavior data from this animal were excluded. 
 
As in the previous section of this chapter, we questioned whether viral-mediated 
overexpression of VGF in sensory neurons would manifest as behavioral 
hypersensitivity.  Unexpectedly, mechanical sensitivity thresholds in all treatment groups 
descended sharply from the initial baseline values over the early testing period (Figure 
2-8).  After three to four weeks, the paw withdrawal threshold values appeared to 
plateau at approximately 60% of the baseline force.  This response pattern was similarly 
reproduced in both hind paws and across treatment groups, including both the naïve and 
vehicle-treated controls.  Given the instability of the threshold values, p values resulting 
from statistical analyses were difficult to interpret and considered potentially misleading.  
For example, post hoc comparisons of two-way repeated measures ANOVA showed a 
significant difference between mechanical threshold values of the left hind paw in the 
hVGF AAV5-VGF group at days 28 and 35 relative to saline-treated hVGF animals (p < 
0.05 and 0.01, respectively).  However, no statistically significant difference was 
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observed when comparing the threshold values of the right hind paw, and hVGF AAV5-
VGF did not significantly differ from the hVGF AAV5-GFP or naïve mVGF groups at any 
time point.  It appears the finding of significance relies more on the unexplained rise in 
the mechanical thresholds of the hVGF saline group during this time frame.  Indisputable 
confirmation of treatment-induced mechanical hypersensitivity could not be meaningfully 
interpreted.    
 
In the tail suspension test, mice innately engage in vigorous escape behaviors but 
eventually succumb to immobility, with longer durations of immobility suggesting a 
heightened degree of behavioral despair.  Decreased immobility times in tail suspension 
and forced swim assays have been induced through intraventricular or hippocampal 
delivery of VGF-derived peptides (Hunsberger et al., 2007; Thakker-Varia et al., 2007).  
As viral transduction of neurons in the hippocampal formation has been observed 
following viral vector delivery through direct lumbar puncture (Schuster et al., 2014a), we 
reasoned that viral-mediated overexpression of VGF in this off-target region could 
manifest as antidepressant behavior.  A large proportion of the mice demonstrated a 
propensity to reach for their tails during the testing session irrespective of treatment 
group (20 of 29 mice, or 69%).  Of these, 7 animals (24%) were able to successfully 
climb onto their tail and grasp the suspension hook for a substantial portion of the testing 
session (range = 51 to 167 seconds, mean = 113 ± 17 seconds).  Given these 7 
individuals “escaped” the stressor, their data were not considered valid and were omitted 
from further analysis.  The omitted subjects included naïve mVGF (n = 2), hVGF with 
AAV5-VGF (n = 2), hVGF with AAV5-GFP (n = 2), and hVGF with saline (n = 1).  In the 
remaining animals, no significant differences in mean immobility times were identified 
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between any of the treatment groups by one-way ANOVA with post hoc multiple 
comparisons (Figure 2-9). 
 
Immunohistochemical analysis was performed to detect the presence of viral-mediated 
gene expression in vector-treated animals.  While highly conserved, variations exist 
between mouse VGF1-617 and human VGF1-615 sequences.  The rabbit anti-TLQP-21 
antibody recognizes an epitope of the VGF-derived peptide that is unique to the rodent 
sequence, while the guinea pig anti-AQEE-30 antibody used in the prior rat experiments 
recognizes rodent or human peptide.  Thus in the humanized VGF-knock-in mice, the 
expression of endogenous human VGF could be discriminated from the viral-driven 
rodent VGF by using the anti-TLQP-21 antisera. 
 
The results of immunohistochemistry are summarized in Table 2-1.  Expression of viral-
mediated GFP was evident in all animals, but anatomic locations were variable.  In one 
subject, GFP-immunoreactivity (-ir) was entirely within somatosensory pathways 
including L4 DRG sensory neurons, dorsal roots, the dorsal horns and columns of the 
spinal cord, and dorsal column nuclei in the brainstem, while in another GFP-ir was 
instead evident in the ventral horns, ventral and lateral columns of the spinal cord, 
cerebellar peduncles, and cerebellum.  Occasional sensory neuron transduction was 
evident in 3 of the 6 animals.  The most reliable tissue for viral transduction was the 
choroid plexus of the fourth ventricle.  Interestingly, the choroid plexus was the only 
tissue in which viral-mediated expression of VGF was observed.     
 
2.2.4 DISCUSSION 
 
	   41 
In this pilot study, we investigated the use of a humanized VGF-knock-in mouse line to 
better visualize the vector distribution and viral-mediated overexpression of rodent VGF 
following intrathecal administration.  Based on previous work with this vector serotype 
and delivery method, we expected viral transduction to be evident in the lumbar dorsal 
root ganglia and spinal cord as well as in off-target supraspinal regions, and the 
overexpression of VGF would manifest through behavioral effects dependent on the 
region affected.  Successful transduction of AAV5-VGF was only evident 
immunohistochemically in the choroid plexus despite the widely distributed and variable 
transduction observed with AAV5-GFP.  A distinct behavioral phenotype was not evident 
in vector-treated mice; however, this lack of desired biological effect is consistent with 
the absence of transgene overexpression within neurons.    
 
It is not clear whether the apparent paucity of neurotropism by AAV5-VGF is a 
consequence of poor transduction, low transgene expression, or failure of the transgene 
to yield bioactive peptides.  While advantageous for its species-specificity, the anti-
TLQP-21 antibody used to immunohistochemically detect viral-mediated gene 
expression recognizes the cognate VGF-derived peptide TLQP-21, but not the 
unprocessed parent peptide (Fairbanks et al., 2014).  Viral-driven VGF protein 
production in neurons may be subject to incomplete or incorrect post-translational 
processing.  Interestingly, viral-driven TLQP-21 was observed within the choroid plexus, 
so appropriate post-translational processing of the VGF transgene product is possible.  
To elucidate whether transduction failure is the limiting step for neuronal VGF 
overexpression, future work using the AAV5-VGF vector should incorporate quantitative 
real-time PCR of DNA extracted from DRG or other relevant tissue to determine the 
number of vector genomes per cell.  Instead of utilizing a primer targeted against the 
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transgene, which presents technical challenges given the sequence similarities between 
human and rodent VGF, primers could be targeted against the viral vector promoter or 
inverted terminal repeat regions.  Decreased transduction efficiency may be potentially 
overcome with a higher vector dose, but aberrant intracellular processing of the 
transgene product may require redesigning the vector construct.  
 
This study also utilized mouse lines on a mixed genetic background.  Congenic mouse 
strains are produced by repeatedly backcrossing a locus of interest, such as a targeted 
mutation, onto a parental inbred strain with the goal of creating a uniform genome that is 
identical to the inbred strain at all loci except that specific genetic region.  A strain is 
considered to be incipient congenic after five generations of backcrossing (with a 
statistical percentage of background genome of 96.9%) and fully congenic after ten 
generations of backcrossing (99.91% background genome).  The mice utilized in this 
study were the offspring of N2 breeders, meaning the parents had been backcrossed for 
two generations.  Further backcrossing was not performed, so the mixed genetic 
background of these mice was statistically 75% recipient strain (C57BL/6) and 25% 
donor strain (129Sv/J).   
 
An unintended consequence of this hybrid genetic background may be variability in 
behavioral outcomes.  The C57BL/6 and 129 mouse strains display phenotypic 
differences in several assays of pain-relevant behavior.  Notably, the two strains show 
significant differences in mechanical sensitivity, with the baseline hind paw withdrawal 
threshold of 129 mice being substantially lower than that of C57BL/6 mice in the von 
Frey filament test (Mogil et al., 1999; Lariviere et al., 2001).  In the tail suspension test, a 
strong tendency toward tail-climbing behavior has been reported for C57BL/6 mice but 
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not in similarly tested 129 mice (Mayorga and Lucki, 2001; Bergner et al., 2010).  With 
the undefined genetic background, individual mice may display a propensity towards 
“129-like” or “C57BL/6-like” behavior independent of the knock-in versus wild-type 
differences in our gene of interest.  It is possible this genetic confound may have 
resulted in sufficient behavior variability to mask more subtle experimental-induced test 
outcomes.   
 
The behavior assays also illustrate some of the challenges involved in evaluation of 
animal behavior and interpretation of the test read-out values.  In the assessment of 
mechanical sensitivity, significant threshold decay from baseline was similarly evident in 
all treatment groups over the first few weeks of the experiment.  Although these values 
seemed to stabilize over the later weeks, the uncertainty in the cause of this change in 
tactile sensitivity precluded meaningful interpretation.  One possibility to explain the 
potentially spurious decline in threshold values is an instrument fault.  Unlike the work 
reported earlier in this chapter assessing mechanosensitivity in rats using classical von 
Frey filaments, these mice were evaluated using an electronic von Frey aesthesiometer.  
The fluctuations in the read-out values may be due to a loss of calibration of the 
electronic instrument (Martinov et al., 2013).  Another possibility, as discussed in the 
section regarding the rats, is anticipatory hypervigilance.  The mechanical sensitivity 
testing was performed in a larger testing room with the possibility of other murine 
experimental work being performed concurrently.  Other stressors, such as unfavorable 
visual, olfactory, or ultrasonic auditory cues, may have adversely conditioned the mice 
and negatively influenced their testing experience independent of the experimental 
treatments (Detloff et al., 2010).   
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Evaluation of the tail suspension assay was complicated by the propensity for tail-
climbing behavior, which ultimately invalidated the trial for multiple mice that reached 
and grasped the suspension hook.  The initial attempt to reach for the tail occurred 
within the first 60 seconds of the trial in 17 of the 20 mice, suggesting the problem would 
not be avoided by decreasing the length of the trial.  To prevent tail-climbing behavior, 
Can and colleagues (2012) reported the successful use of cylinders of polycarbonate 
tubing placed as a baffle around the tail prior to suspension.  This may represent an 
easily obtained, practical solution for future testing of C57BL/6 background mice.     
 
Several mice representing various treatment groups also spent very little time immobile 
(< 10% of the total trial time).  Typically, vigorous escape-oriented behaviors are 
interspersed with periods of immobility that increase in length as the trial progresses.  
The low immobility times suggest the testing session may have been too short, as not all 
individuals succumbed to the inescapable stress.  In future work, extending the length of 
the testing session from 3 minutes to 6 minutes may better differentiate mice with and 
without depression-like behavior. 
 
2.3.1  UNEXPECTED SENSORY NEURONOPATHY FOLLOWING AAV9-MEDIATED 
GENE TRANSFER 
 
AAV vectors have emerged as powerful vehicles for genetic manipulation of neurons, 
mediating efficient, stable, and nonpathogenic transduction (Daya and Berns, 2008; 
Schultz and Chamberlain, 2008).  Differential targeting of subtypes of primary sensory 
neurons by AAV5 and AAV8 following intrathecal delivery by direct lumbar puncture has 
been demonstrated (Vulchanova et al., 2010; Schuster et al., 2013).  However, 
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transduction of these DRG neurons required pretreatment with intravenous mannitol, a 
hyper-osmotic blood-brain barrier interruptive reagent that has also been used to 
enhance AAV distribution in the brain and spinal cord (Kroll and Neuwelt, 1998; 
Mastakov et al., 2001; Fu et al., 2003). 
 
Interestingly, recent reports have suggested that another serotype, AAV9, is able to 
cross the blood-brain barrier in neonatal and adult animals without the concurrent use of 
any permeabilizing reagents (Gray et al., 2011b; Dayton et al., 2012).  While successful 
transduction of primary sensory neurons by AAV9 vectors has been demonstrated in 
rodent and non-human primate models (Hirai et al., 2012, 2014; Gray et al., 2013), the 
expression pattern of AAV9-mediated gene transfer to sensory neurons had not been 
characterized.  The goal of the present study was to evaluate the ability of AAV9-GFP to 
transduce primary sensory neurons and off-target supraspinal regions following 
intrathecal or intravenous delivery.  However, during the course of immunofluorescence 
image analysis of DRG sections, aberrant labeling of neuronal Nissl substance was 
identified in several animals (Figure 2-10), prompting further evaluation.  The purpose of 
this report is to describe the unexpected sensory neuronopathy associated with AAV9-
mediated expression of GFP. 
 
2.3.2 METHODS 
 
For this retrospective investigation we utilized tissue cryosections remaining from 
several experiments, summarized in Table 2-2.  The experimental procedures within 
these studies were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of Minnesota.   All experiments utilized adult male mice (20–
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25g; Harlan Labs, Madison, Wisconsin USA).  AAV9-GFP was purchased from the 
University of Pennsylvania Vector Core (AAV9.CB7.Cl.eGFP.WPRE.rBG; Philadelphia, 
Pennsylvania USA).  AAV9-human arginine decarboxylase (hADC)-GFP and AAV5-
CAG-GFP were acquired from the University of Florida Vector Core Lab of the Gene 
Therapy Center (Gainesville, Florida USA).  Animals were sacrificed by perfusion fixation 
as described within earlier sections of this chapter.  Harvested tissues were 
cryosectioned (14 µm) and thaw-mounted onto gelatin-coated slides.   
 
In the inciting experiment, C57BL/6 mice received AAV9-GFP through intrathecal (IT) or 
intravenous (IV) routes of delivery and in the presence or absence of mannitol 
pretreatment (Schuster et al., 2014b).  The viral dose was 3.3 x 1011 vector genomes per 
injectate.  These mice were maintained until a 3-week endpoint.  As shown in the 
fluorescence micrographs in Figure 2-10, DRG immunohistochemistry included chicken 
anti-GFP primary antisera, 1:1000 (ab13870; Abcam, Cambridge, Massachusetts USA) 
with Cy2-conjugated secondary antisera, 1:300 (Jackson ImmunoResearch, West 
Grove, Pennsylvania USA), and Nissl staining with NeuroTrace® 435/355 Blue 
(Molecular Probes, Inc., Eugene, Oregon USA). 
   
Following the initial analysis, additional DRG cryosections were evaluated from other 
experimental cohorts.  Cohort B was composed of C57BL/6 mice that received AAV9-
GFP (1.7 x 1011 vector genomes per injectate) by intrathecal delivery with mannitol 
pretreatment and with a 6-week endpoint (Schuster et al., 2014b).  The vector was from 
the same vendor but an earlier supplier lot.  Cohort C represented a subsequent 
experiment that utilized the same batch of AAV9-GFP as the initial cases but at a 1:50 
dilution.  In this study, ICR/CD-1 mice received AAV9-GFP, AAV9-human arginine 
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decarboxylase (hADC)-GFP, or saline with no pretreatment (Peterson et al., 2014).  
Incidentally, the reporter gene in the AAV9-hADC-GFP construct failed to express.  
Finally, Cohort D was composed of banked DRG sections from C57BL/6 mice that 
received intrathecal AAV5-GFP with mannitol pretreatment (as in Vulchanova et al., 
2010; Schuster et al., 2014a).       
   
Histopathology.  In Cohort A, slides of L4 dorsal root and trigeminal ganglia were 
selected from the remaining tissues to include 3 to 6 sections from each animal as 
equally spaced as possible within the available set to reduce unintentional bias.  The 
minimum distance between ganglia sections was 42 µm.  Limited sections of other 
tissues from each animal, including spinal cord, liver, skeletal muscle, ileum, and colon, 
were included for general screening.  For all other cohorts, only DRG sections were 
evaluated.  The glass slides were submitted to the University of Minnesota Comparative 
Pathology Shared Resource for routine hematoxylin and eosin staining.  The tissue 
thickness precluded sharp focus and along with the gel coating caused variation in the 
staining quality.   
 
The ganglia sections were scored by a trained, blinded investigator for the presence and 
severity of mononuclear infiltration and neuron loss based on the lesion parameters 
summarized in Table 2-3.  The overall variance in lesion severity was evaluated to fit the 
range of observed lesions into a qualitative, ordinal scoring system (Gibson-Corley et al., 
2013).  An ordinal score of 1 indicated the presence of increased numbers of 
mononuclear cells with no clear organization and no evidence of neuronal loss.  
Sections with evidence of neuronal loss and replacement by compact, discrete nodules 
of mononuclear satellite cells (nodules of Nageotte) were assigned a score of 2 if solitary 
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and 3 if multiple.  An ordinal score of 4 was reserved for sections with multifocal 
neuronal loss along with exuberant mononuclear infiltration, including within the 
subcapsular space.  All stained sections were scored for each animal.  Given the limited 
number and varying quality of fields available for review, the maximum score evident in 
any of the sections was assigned for the whole tissue of that animal.    
 
2.3.3 RESULTS 
 
Group designations for the sensory ganglia assessed in the initial investigation included 
naïve (n = 1), IV vector pretreated with saline (n = 4) or mannitol (n = 4), and IT vector 
pretreated with saline (n = 4) or mannitol (n = 2).  This final group was reduced in size 
due to the loss of two animals prior to the 3-week endpoint; one animal was found 
deceased and a second was euthanized due to progressive seizure activity.  
Regrettably, issues from these two animals were not available for analysis. 
Lesions in sensory ganglia ranged in severity and included infrequent, discrete nodules 
of residual satellite glial cells replacing solitary neurons (nodules of Nageotte) to more 
exuberant mononuclear infiltration with multifocal neuronal degradation and loss (Figure 
2-11 A-C).  In the L4 DRG, lesions were restricted to animals that received AAV9-GFP 
by intrathecal administration (Figure 2-11 D) and seemed to be more consistently severe 
in the mannitol pre-treatment group.  However, this interpretation may be biased by the 
limited sample size.  The trigeminal ganglia were less severely affected with neuronal 
loss evident in only one animal (Figure 2-11 E), although low-grade lesions were also 
observed in one subject with intravenous AAV9-GFP and mannitol.  No lesions were 
evident on cursory examination of spinal cord, liver, skeletal muscle, or enteric tissues, 
	   49 
although the variation in staining quality and thickness of the tissue sections may have 
masked subtle abnormalities. 
 
Histopathological examination of L4 DRG was expanded to include several other 
experimental cohorts for comparison (Figure 2-12).  In Cohort B, all subjects (n = 4) 
received a similar IT dose of AAV9-GFP following mannitol pretreatment but from a 
different supplier lot.  The animals were also maintained for 6 weeks post-injection 
instead of 3 weeks.  Unlike the inciting experiment, no mortality was reported.  Neuronal 
loss was still apparent but less extensive.  In Cohort C, mice of a different strain were 
administered the same vector IT as in the initial experiment at a reduced dose and 
without mannitol pretreatment.  Neuronal degradation and loss was evident in all animals 
that received the AAV9-GFP vector (n = 3).  No lesions were observed in animals 
treated with IT AAV9-hADC-GFP (n = 3) or saline (n = 2).  In Cohort D, all the mice were 
treated with a different serotype of reporter vector, AAV5-GFP, which was administered 
IT and with mannitol pretreatment.  No lesions were observed (n = 5).   
 
Ideally, the tissue scoring system should have been compared to a relevant parameter 
of disease severity, such as behavioral or electrophysiological output measures, in order 
to validate whether the scoring method was meaningful.  However, no such pathobiology 
data was collected.  Quantitative analysis for evaluation of cell loss was also beyond the 
scope of this study.  Therefore, the distinction in the number of neurons affected in an 
individual section may be arbitrary.  Reducing the scoring system to a binomial method, 
the data were summarized based on the presence or absence of distinct neuronal 
damage (an ordinal score of 2 or greater).  The incidence of sensory neuronopathy 
within the various treatment paradigms is summarized in Table 2-4.     
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2.3.4 DISCUSSION 
 
We provide evidence that intrathecal administration of AAV9-GFP in mice was 
associated with unexpected sensory neuron degeneration and loss of variable severity.  
Neuron damage was observed with the use of two different supplier lots of the same 
viral construct, several vector dosages, and two strains of mice.  No lesions were 
observed in the sensory ganglia of mice that received a different AAV9 construct in 
which GFP failed to express, AAV5-GFP, or saline by the same delivery method.  
However, this retrospective assessment was limited to available tissues, and clear 
relationships between lesion severity and the vector source, vector dose, or mouse 
strains could not be inferred.   
 
The diagnostic quality of the cryosections was hampered by the tissue thickness, which 
while appropriate for immunofluorescence, was approximately three times thicker than a 
standard histologic section.  Another challenge to morphological interpretation was cell 
shrinkage and resulting anatomical distortion, which is a known drawback of the 
perfusion fixation method in rodents (Scouten, 2010).  Despite the obscured cellular 
details, histological staining demonstrated the occurrence of residual nodules of 
Nageotte, compact areas of satellite cell proliferation that remain at sites of DRG neuron 
loss (Ellison et al., 2008).  In other sections, more exuberant mononuclear cells were 
evident within the subcapsular space suggestive of inflammatory infiltrates.  It is unclear 
whether these lesions result from separate pathological processes or represent different 
temporal stages of the same process. 
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Potential toxicities from viral vector administration may result from the delivery 
procedure, the viral vector, or the specific transgene (Pleticha et al., 2014a).  In these 
mice, intrathecal delivery was performed by direct lumbar puncture, which unlike 
periganglionic injection, has not been associated with parenchymal injury to the DRG.  
Lesions were also absent in mice that had received other vectors or vehicle controls by 
the same injection method.  Potential contamination of the viral vector due to a fault in 
the purification method could not be excluded, as both vector lots were acquired from 
the same vendor.  However, no lesions were evident on cursory examination of systemic 
tissues in animals with IV administration of vector.  Damage as a result of the viral vector 
itself also seems unlikely.  Recombinant AAV vector genomes display inefficient 
integration into the host chromosome, persisting instead in episomal form (McCarty et 
al., 2004), so the risk of insertional mutagenesis that may compromise the viability of 
transduced cells is very low.  Recombinant AAV vectors also do not contain viral genes, 
and have been noted for their inability to elicit cellular immune responses in rodents 
(Tenenbaum et al., 2003; Beutler, 2010).  AAV vector capsids do not replicate after 
cellular transduction and are likely cleared from tissues relatively quickly. 
 
The specific transgene involved in all instances of sensory neuronopathy was the 
reporter gene GFP, which is classically considered to be biologically inert (Marshall et 
al., 1995).  However, neurotoxicity resulting from excessive transgene expression has 
been reported for fluorescent reporter proteins (Furuta et al., 2001; Goto et al., 2003; 
Klein et al., 2006; Comley et al., 2011) and other transgene products (Grimm et al., 
2006; Ulusoy et al., 2009; Ehlert et al., 2010).  Cell stress and subsequent death result 
from excessive consumption of important cellular resources and oversaturation of 
endogenous pathways.  The high efficiency of the AAV9 vector combined with the strong 
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CB7 promoter may have caused overproduction of the fluorescent reporter protein within 
certain cells.  This pathogenesis is consistent with the observation of chromatolytic 
neurons with abundant cytoplasmic GFP, and may explain the finding of isolated, 
tombstone-like nodules of Nageotte in the absence of inflammatory infiltrates. 
 
Expression of foreign proteins may elicit a cellular immune response, particularly if the 
vector has tropism for antigen-presenting cells.  Notably, recent reports caution the use 
of AAV vectors with broad tropism to mediate expression of a non-self protein in the 
brain, as off-target transduction of antigen-presenting glial cells resulted in a destructive 
neuroinflammatory response in rats and nonhuman primates (Hadaczek et al., 2009; 
Cielsielska et al., 2013; Samaranch et al., 2014).  Sensory neurons, like neurons of the 
central nervous system, fail to express major histocompatibility complex (MHC) 
molecules (Turnley et al., 2002), and are therefore unlikely to be involved in immune 
surveillance.  However, satellite glial cells in the sensory ganglia, which tightly envelop 
the neuronal cell bodies, share some properties of antigen presenting cells (van Velzen 
et al., 2009).  It seems possible that transduction of satellite glial cells by AAV9 encoding 
a foreign protein could elicit a cellular immune response.  Indeed, careful scrutiny of the 
immunofluorescence micrographs from the inciting experiment revealed several 
instances of crescentic cells immediately adjacent to sensory neurons with GFP-positive 
cytoplasm, morphologically consistent with satellite glial cells (Figure 2-13).  Similar cells 
were not apparent in immunofluorescence micrographs within areas of widespread 
neuronal loss, but it seems likely that such cells would have been destroyed.  Further 
analysis is warranted to immunohistochemically confirm the identity of the putative 
satellite glial cells and determine the extent of AAV9-mediated transduction of this cell 
population. 
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No microscopic lesions were observed in mice that received a different AAV9 vector by 
the same route of administration, despite the vector encoding two non-syngeneic 
proteins.  However, several uncertainties exist making a meaningful comparison 
between these vectors challenging.  Each AAV9 vector was from a different vendor 
source.  Data were not available on the tropism or expression levels of AAV9-hADC-
GFP other than confirmation that the reporter gene product, encoded by the second 
gene after the promoter in the construct, was not detectable.  The production of hADC 
may not have been so extensive as to cause cellular exhaustion.  Similarly, the human 
and murine sequences of arginine decarboxylase may be sufficiently similar to not 
induce an immune response.  Interestingly, the derivation product of hADC, agmatine, 
shows various neuroprotective effects (Hong et al., 2014), and while speculative, it 
seems possible that overexpression could potentially mitigate lesion formation.  A more 
comprehensive investigation to clarify the relationships between vendors, tropism, dose, 
and immunogenicity of transgene products for this vector serotype may be warranted. 
 
The pathobiological consequences of this unexpected sensory neuronopathy are 
unclear, as no behavioral outcome measures were available from the affected animals 
and the overall extent of neuron loss could not be quantified.  The sudden mortality and 
progressive seizure activity of animals within the treatment group with the least 
impedance to vector biodistribution within the nervous system are certainly suspicious, 
and may suggest more extensive neuronal damage than in just the sensory ganglia.  
Random sensory neuronopathy may complicate data interpretation, particularly in 
studies investigating sensory neuron signaling.  High efficiency GFP-encoding vectors 
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may also be inappropriate as transduction controls, especially if compared to viral-
mediated expression of syngeneic proteins. 
 
CONCLUSIONS 
 
To test the hypothesis that VGF activity in sensory neurons modulates nociception and 
hypersensitivity in rodents, as measured by assays of pain-relevant behavior, we utilized 
viral-mediated gene transfer techniques to induce VGF overexpression in DRG sensory 
neurons.  We provide evidence that intrasciatic administration of AAV5 yields 
predominately local transduction with inefficient and variable gene transfer to sensory 
and motor neurons.  Intrathecal administration of AAV5-VGF by direct lumbar puncture 
resulted in successful transduction of the choroid plexus in the fourth ventricle.  
However, sensory neuron transduction by AAV5-VGF was not evident and the 
mechanisms precluding transgene expression in this cellular population are unclear.  
The potential for supraspinal structures to influence the behavior outcomes of spinal 
reflex-withdrawal assays may also warrant further consideration. 
 
Any observed differences in mechanosensitivity thresholds between animals receiving 
the AAV5-VGF vector and those receiving saline were insufficiently robust to be 
statistically significant.  However, this may be partly due to the limited group sizes 
available for final analyses, which were as low as three animals per group in some 
studies, and the imbalance between the numbers of treated and control animals.  The 
data from these small, inconclusive trials can be used to estimate the needed sample 
sizes examining mechanosensitivity thresholds, benefiting future work.  Sample sizes 
can be estimated using the difference in the means between groups (δ), the standard 
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deviation common to both treated and untreated groups (S), the desired significance 
level (α), and the power of the test (1-β).  In the first rat experiment, the difference in the 
mean mechanosensitivity thresholds was most pronounced at 42 days post-injection 
(Figure 2-2 A).  The sample size needed to demonstrate a significant difference between 
rats treated with intrasciatic AAV5-VGF or saline is 15 rats per group (α = 0.05, 1-β = 
80%, δ = 0.215, S = 0.21).  Applying the same approach to the mouse pilot study and 
using the day 42 data (Figure 2-8 A, C), the sample size needed to demonstrate a 
significant difference between mice treated with intrathecal AAV5-VGF or saline is 18 
mice per group (α = 0.05, 1-β = 80%, δ = 2.05, S = 1.96).  Viral-mediated gene transfer 
was not successful in all animals, so the group sizes would have to be adjusted 
accordingly to ensure sufficient samples.  As the success rate of viral gene transfer in 
the rat experiments was approximately 50%, and the number of experimental and 
control animals should be matched, the estimated total number of rats needed to pursue 
the differences in mechanosensitivity thresholds between AAV5-VGF and saline 
treatments would be at least 45 (15 control + 15 successful AAV5-VGF + 15 
unsuccessful AAV5-VGF).  Another 30 rats would be needed if another vector treatment 
group (e.g. AAV5-GFP) was included for comparison. 
 
Variability in the quality of AAV vectors between batches and vendors became 
increasingly evident throughout the course of this work.  While we demonstrated 
repeated neurotoxicity associated with AAV9-mediated transduction of DRG sensory 
neurons and putative satellite glial cells, no sensory neuron damage was observed in 
later experimental work using the same serotype from the same vendor.  The apparent 
biodistribution and intensity of GFP expression following intrathecal delivery of AAV5-
GFP in mice also differed between the present experiments reported in section 2.2 and 
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in our previous work (Vulchanova et al., 2010), despite using the same vector source, 
vector dose, delivery method, and strain of mice.  These findings raise some concerns 
regarding the use of AAV vectors in the DRG, and a more thorough assessment of 
quality control and method standardization is warranted. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1, Behavior assay outcomes following intrasciatic administration of AAV5-VGF 
(n = 10), AAV5-GFP (n = 6), or saline (n = 4).  (A, left) Mechanosensitivity thresholds 
determined by von Frey filament application were decreased for animals treated with 
AAV5-VGF as early as day 14 post-injection, but this trend was not statistically 
significant at any time point.  A similar declining trend was observed for the AAV5-GFP 
treatment group at later time points.  The grey solid line indicates the maximum possible 
value from the filament series.  BL designates baseline measurements preceding 
intrasciatic injection.  (A, right) Comparison of mechanosensitivity thresholds between 
the hind paws revealed striking similarities in responses despite the unilateral vector 
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administration.  Closed symbols represent the left, affected hind paw (ipsilateral), and 
open symbols represent the right, naïve hind paw (contralateral).  (B) The area under 
the paw withdrawal threshold curve was calculated for each subject to derive group 
averages.  No significant differences were evident.  (C) The latency to withdrawal of 
either hind paw from a radiant light heat source did not vary significantly over time. 
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Figure 2-2, Behavior assay outcomes for animals with immunohistochemically 
confirmed vector transduction; AAV5-VGF (n = 5), AAV5-GFP (n = 3), and saline (n = 3).  
(A, left) Declining trends in mechanosensitivity thresholds were still evident in the 
vector-treated groups.  The changes in tactile sensitivity were mirrored in the 
contralateral (right) hind paws, as seen in (A, right).  (B) Group means for the area 
under the paw withdrawal threshold curve were not significantly different.  (C) Variations 
in the latency to paw withdrawal were more pronounced due to the reduced group sizes.  
There was no evidence of thermal hyperalgesia.    
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Figure 2-3, Representative immunofluorescence sections of rat sciatic nerves.  (A) 
Widespread AAV5-mediated transfer of GFP within the sciatic nerve; scale bar = 250 
µm.  Higher magnification of tissue double-labeled with anti-GFP (B) and anti-MBP (C) 
suggests transduction of Schwann cells.  Merged pseudocolored channels shown in (D); 
scale bar = 25 µm.  (E) Multifocal AAV5-mediated transfer of VGF in the sciatic nerve; 
scale bar = 250 µm.  Double-labeling with anti-VGF (F) and anti-MBP (G) revealed 
limited colocalization in myelin sheaths.  Merged pseudocolored channels shown in (H); 
scale bar = 25 µm.  Corresponding saline-injected controls for anti-GFP (I) and anti-VGF 
(J); scale bar = 250 µm.  
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Figure 2-4. Representative images of the ipsilateral fifth lumbar (L5) DRG.  (A) GFP-ir 
was observed in very low numbers of scattered sensory neurons in animals treated with 
AAV5-GFP.  As expected, GFP-ir was absent in other treatment groups (E, I).  (B, F, J) 
Clear overexpression of VGF-ir was not evident between treatment groups.  (C, G, K) 
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Expression levels of CGRP, a nociceptive signaling neuropeptide, were similar between 
treatment groups.  (D, H, L) Corresponding images of NeuroTrace labeling; scale bar = 
200 µm.  (M) Semi-quantitative analysis of VGF-ir revealed similar levels of expression 
between treatment groups.  Lines represent group means calculated from all individuals.  
Individual animals represented by star symbols (★) are those that were excluded in 
previous behavior analysis.  Please refer to the text for exclusion criteria.  (N) Semi-
quantitative image analysis of CGRP-ir revealed no difference between treatment 
groups.   
 
 
 
 
 
  
	   63 
 
 
 
 
 
 
Figure 2-5, (A) Limited GFP-ir was evident in the dorsal root and superficial laminae of 
the ipsilateral dorsal horn.  Ventral horn motor neurons were rarely transduced (inset, 
scale bar = 50 µm).  (B) Corresponding saline-injected control.  Transduced VGF (C) 
could not be discriminated from endogenous protein in saline controls (D); scale bar = 
250 µm.  
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Figure 2-6, Behavior assay outcomes following intrasciatic administration of AAV5-VGF 
(n = 12) or saline (n = 4).  (A, left) Mechanosensitivity thresholds were more stable over 
time in the second experimental cohort.  (A, right) Paw withdrawal thresholds were very 
similar between the left hind paw (ipsilateral, closed symbols) and right hind paw 
(contralateral, open symbols).  (B) As expected based on the appearance of the data, 
there were no significant differences in the area under the PWT curves.  (C) All animals 
were monitored for 60 seconds for acetone-evoked behaviors (AEB), but responses 
were limited to rapid initial flinching and brief grooming of the paw.  No group average 
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exceeded 2.5 seconds of total evoked behavior time (grey line).  Prolonged evoked 
behaviors consistent with cold allodynia were not observed.      
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Figure 2-7, Behavior assay outcomes for animals with immunohistochemically 
confirmed vector transduction; AAV5-VGF (n = 8) and saline (n = 4).  Limiting analysis to 
animals with evidence of VGF-ir in the sciatic nerve did not meaningfully alter the results 
of the mechanosensitivity assay (A), comparison of the area under the PWT curves (B), 
or assessment of acetone-evoked behaviors (C).  No significant differences were evident 
between treatment groups.      
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Figure 2-8, Mechanosensitivity thresholds determined by an electronic von Frey 
aesthesiometer.  (A-D) In all treatment groups, paw withdrawal thresholds were 
consistent between the left hind paw (closed symbols) and right hind paw (open 
symbols).  Thresholds unexpectedly declined sharply from baseline values over the first 
three weeks, then became relatively stable for the remainder of the experiment.  (E) 
Within each group, mechanosensitivity thresholds were significantly lower than baseline 
at 3- and 6-weeks post-injection.  There was no significant difference between 3- and 6-
weeks post-injection (paired two-tailed t-test, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = 
not significant). 
  
	   68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9, Immobility times during the tail suspension assay.  Antidepressant-like 
behavioral effects were not evident in any treatment group.    
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Anatomic Area AAV5-GFP AAV5-VGF 
Lumbar 
     L4 DRG 3 / 6 – 
     Spinal cord 5 / 6 – 
Supraspinal 
     Choroid plexus 6 / 6 5 / 7 
     Brainstem 3 / 6 – 
     Cerebellum 1 / 6 – 
     Midbrain – – 
     Forebrain – – 
Systemic 
     Liver – – 
   
 
 
Table 2-1, Immunohistochemical detection of viral-driven gene expression in vector-
treated hVGF mice.  The values indicate the total number of animals in which 
immunoreactivity was observed within the specified tissue out of the total number of 
animals in the group.  The “–“ symbol indicates no immunoreactivity was evident in the 
entire group.        
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Figure 2-10, (A) AAV9-GFP mediated gene transfer to the mouse L4 DRG and (B) 
corresponding NeuroTrace labeling.  Normal appearing transduced cells lie adjacent to 
mottled regions with indistinct cellular margins and uncharacteristic neuronal loss (dotted 
yellow outlines); scale bar = 100 µm.  At higher magnification, labeling for GFP (C) and 
NeuroTrace (D) reveals GFP-positive neurons with absent or marginalized Nissl 
substance, suggestive of chromatolysis (yellow arrows); scale bar = 100 µm.       
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Cohort Strain Vector Lot Dose Delivery 
A C57BL/6 AAV9-GFP 2 3.3 x 1011 IV, IT, ± Mannitol 
B C57BL/6 AAV9-GFP 1 1.7 x 1011 IT + Mannitol 
C ICR/CD-1 AAV9-GFP 2 6.6 x 109 IT 
  AAV9-hADC-GFP – n/a IT 
D C57BL/6 AAV5-GFP – ~1011 IT + Mannitol 
 
 
Table 2-2, Source of histopathology samples according to mouse strain, vector, and 
administration method. 
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Score Lesion Rating Description 
0 None No microscopic lesions 
1 Minimal Generally increased mononuclear cells without neuron replacement or loss 
2 Mild Distinct nodular aggregate of mononuclear cells replacing one neuron 
3 Moderate 
Discrete nodular aggregates of 
mononuclear cells replacing more than 
one neuron 
4 Marked 
Disseminated mononuclear infiltrates 
and nodular aggregates replacing at 
least three neurons 
 
 
Table 2-3, Ordinal scores based on the distribution of lesions within sensory ganglia. 
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Figure 2-11, Hematoxylin and eosin scoring of mouse L4 DRG and trigeminal ganglia 
from Cohort A.  (A) Naïve animal with no evidence of disease in the L4 DRG.  (B) A 
single sensory neuron is replaced by a nodular aggregate of mononuclear cells (nodule 
of Nageotte, arrow).  The DRG section represents a lesion score of 2.  (C) Multiple 
neurons are replaced by dense aggregates of mononuclear cells (arrows), which also fill 
the subcapsular space (arrowhead).  The DRG section represents a lesion score of 4.  
Some differences in appearance are due to variation in staining quality and cellular 
shrinkage artifacts.  Thickness of sections (14 µm) precluded sharp focus.  Scale bar = 
100 µm.  (D) Lesions in the L4 DRG were associated with intrathecal delivery of AAV9-
GFP.  (E) In the trigeminal ganglia, minimal to mild disease was evident in vector-treated 
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animals by either route of administration.  An ordinal score of 2 or greater is indicative of 
neuronal loss.    
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Figure 2-12, Hematoxylin and eosin scoring of mouse L4 DRG from retrospective 
Cohorts B, C, and D.  Lesions were associated with IT administration of AAV9-GFP from 
either supplier lot.  No lesions were observed following IT delivery of AAV9-hADC-GFP, 
saline, or AAV5-GFP. 
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Vector Cohort Route Pretreatment Neuronal  Loss % 
AAV9-GFP (Lot 2) A IV Saline 0 / 4 0 
 A IV Mannitol 0 / 4 0 
 A IT Saline 2 / 4 50 
 A IT Mannitol 2 / 2 100 
 C IT None 3 / 3 100 
AAV9-GFP (Lot 1) B IT Mannitol 2 / 4 50 
AAV9-hADC-GFP C IT None 0 / 3 0 
AAV5-GFP D IT Mannitol 0 / 5 0 
Saline C IT None 0 / 2 0 
Naïve A – – 0 / 1 0 
 
 
Table 2-4, Scoring of L4 DRG for the presence or absence of neuronal loss. 
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Figure 2-13, Putative AAV9-GFP mediated gene transfer to satellite glial cells in L4 
DRG.  Panels (A) and (B) show the original immunofluorescence micrograph with a 
yellow square indicating the location of the digitally enlarged images shown to the right.  
White dotted lines outline fusiform cells with Nissl-stained nuclei (magenta) that are 
closely associated with neuronal cell bodies, consistent morphologically with satellite 
glial cells.  The cytoplasm of these cells is GFP-positive (green).  Scale bars = 100 µm.   
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Chapter 3 
 
 
Antibiotic-induced visceral hypersensitivity 
 
 
3.1  Assessment of cutaneous referred allodynia in a murine model of antibiotic-
induced visceral hypersensitivity 
 
3.2 Novel utilization of a forelimb grip force assay to monitor antibiotic-induced 
visceral hypersensitivity in mice 
 
3.3 Semi-quantitative image analysis of L6 dorsal root ganglion sensory neurons in a 
murine model of antibiotic-induced visceral hypersensitivity 
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SUMMARY 
 
Deliberate antibiotic-induced perturbation of the gut microflora has been associated with 
the development of colonic hypersensitivity in murine models.  We hypothesized that 
VGF plays a functional role in modulating nociception and hypersensitivity in viscero-
specific sensory neurons.  Antibiotic-induced dysbiosis in mice was not reliably 
associated with a behavioral phenotype of referred cutaneous allodynia of the abdomen 
or of axial stretching-induced discomfort.  Other factors likely contributed to the lack of 
reliability of the dysbiotic model, including potential variability in the basal gut microflora.  
Thorough characterization of the microbial changes, including evaluation for pathogenic 
overgrowth, would complement and inform future work.  Antibiotic treatment and 
presumed dysbiosis were associated with upregulation of CGRP, SP, and VGF in 
predominantly small-diameter sensory neurons of the sixth lumbar DRG.  VGF 
expression was observed throughout the range of neuron sizes and colocalization with 
SP was limited, suggesting a role for VGF beyond peptidergic sensory neurons.  
Increased expression of nociceptive neuropeptides supports the potential utility of this 
experimental model for assessing visceral hypersensitivity, provided an appropriate 
behavioral assay is identified.  As TRPV1 expression was unchanged following antibiotic 
treatment, the value in antemortem testing with capsaicin is unclear.   
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INTRODUCTION 
 
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder, 
with key symptoms including abdominal pain or discomfort and altered lower bowel 
function (Sayuk and Gyawali, 2015).  The prevalence is estimated to be 10-15% in 
Western countries, although as few as 25% of IBS sufferers actually seek professional 
care (Hungin et al., 2005).  The multifactorial pathogenesis of IBS is incompletely 
understood, but involves psychosocial factors, altered signaling between the gut and 
brain, alterations in the normal composition of the gut commensal microbiota, and low-
grade intestinal immune activation (Aguilera et al., 2015).     
 
The neurobiological mechanisms of visceral pain differ from those involved in somatic 
pain, and the role of VGF-derived peptides in viscero-specific sensory neurons has not 
been investigated.  As in our other work investigating the role of VGF in somatic sensory 
neurons (predominantly those of the sciatic nerve), we hypothesized that VGF plays a 
similar functional role in modulating nociception and hypersensitivity in viscero-specific 
sensory neurons.  To explore this hypothesis, we utilized a mouse model originally 
developed to better understand the interplay between visceral hypersensitivity and 
altered intestinal microbiota in IBS.  
 
3.1.1 ASSESSMENT OF CUTANEOUS REFERRED ALLODYNIA IN A MURINE 
MODEL OF ANTIBIOTIC-INDUCED VISCERAL HYPERSENSITIVITY 
 
Deliberate antibiotic-induced perturbation of the gut microflora has been associated with 
the development of colonic hypersensitivity in murine models (Verdú et al., 2006; 
	   81 
Aguilera et al., 2015).  In these reports, visceral sensitivity was assessed through 
responses to intraperitoneal acetic acid, intracolonic capsaicin, or colorectal distension 
via electromyography.  However, these behavior assays may reflect a greater response 
of the somatic peritoneum than of the visceral organ of interest, or can be technically 
demanding, requiring intubation of the distal intestinal tract or surgery, respectively.  
Chemical stimulation assays are also typically performed once with short survival times 
after visceral stimulation due to ethical considerations, precluding their use in serial 
monitoring of progressive hypersensitivity development.   
 
An alternative, simple, viscero-specific behavior assay proposed by Laird and colleagues 
(2001) is the examination of referred pain to the abdominal body wall using standardized 
von Frey filaments.  Inspired by these findings, we questioned whether antibiotic-induced 
dysbiosis and subsequent visceral hypersensitivity could be monitored non-invasively 
through evaluation of referred cutaneous allodynia.  
 
3.1.2 METHODS 
 
Animals.  The experimental procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota.  Adult male C57BL/6 
mice (20–25g; Harlan Labs, Madison, Wisconsin USA) were maintained in a 
conventional vivarium with a 12:12 light/dark cycle (lights on at 07:00 h) and ambient 
temperature of 21±2°C.  The animals were socially housed in groups of 3–4 in 
transparent plastic cages with corncob bedding, compact cotton nesting material, and ad 
libitum access to water and standard rodent chow.  The mice were allowed to habituate 
for at least 3 days under these conditions before the start of experimental manipulations.   
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Antibiotic administration.  Mice received a combination of non-absorbable antibiotics 
by oral gavage once daily for ten days, in accordance with the method described by 
Verdú and colleagues (2006).  Bacitracin and neomycin were diluted in sterile water 
(each to 4 mg/mL), with the addition of pimaricin (0.2 mg/mL) to prevent yeast 
overgrowth.  For the final five days, the antibiotic concentrations were reduced to 
bacitracin 2 mg/mL, neomycin 2 mg/mL, and pimaricin 0.1 mg/mL.  Control animals 
received sterile water (vehicle).  The gavage volume was 100 µL per mouse.  
Alternatively, mice received the same combination of non-absorbable antibiotics in 
drinking water for seven days (Bercik et al., 2011).  The concentrations throughout were 
bacitracin 5 mg/mL, neomycin 5 mg/mL, and pimaricin 0.1 mg/mL.  The medicated water 
was changed daily.  Control animals received non-medicated water.  
 
To examine whether exposure to fecal pellets from mice without altered gut flora could 
protect against the antibiotic-induced changes in visceral sensitivity, select antibiotic-
treated mice were cohoused with control mice.  To replicate this exposure in select mice 
with medicated water, used bedding from cages with non-medicated water was 
transferred daily to cages with medicated water. 
 
Mechanical stimulation of the abdomen.  The frequency of withdrawal responses to 
the application of a von Frey filament to the abdomen was examined as a test of referred 
cutaneous allodynia (Laird et al., 2001).  The filament was applied to the mid to lower 
abdomen for 1 to 2 seconds with a stimulus interval of at least 10 seconds.  In most 
experiments, a von Frey filament with bending force of 0.16 g (filament number 3.22) 
was employed except in Cohorts 8 and 9, which used a 0.07 g (2.83) filament (Stoelting 
Co., Wood Dale, Illinois USA).  The filament was applied 10 times, with care taken to not 
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stimulate the same point twice in succession.  The behavior resulting from application of 
the filament was recorded by the experimenter blinded to the experimental condition. 
 
Chemical stimulation of the colon.  In certain experimental cohorts, spontaneous 
behaviors were evoked through the instillation of capsaicin (0.125% or 0.30% w/vol 
dissolved in 10% ethanol, 10% Tween 80, and 80% saline; Laird et al., 2001).  Just prior 
to the intracolonic administration of capsaicin, petroleum jelly was applied in the perianal 
area to avoid accidental stimulation of somatic areas.  A fine cannula with a rounded tip 
was gently introduced 4 cm into the colon via the anus, and the capsaicin solution was 
slowly injected.  Spontaneous behavior was observed directly for 20 minutes by an 
experimenter blinded to the experimental condition.  Postures quantified as capsaicin-
induced pain-related behavior included licking of the abdomen, abdominal retractions, 
stretching of the abdomen, or squashing of the lower abdomen against the floor.  Mice 
treated with capsaicin were sacrificed immediately following the behavior assessments. 
 
Statistical analysis.  Data were entered into a spreadsheet for analysis.  Statistical 
tests were performed using GraphPad Prism (version 5.0d, GraphPad Software, San 
Diego, California USA, www.graphpad.com).  Groups were compared by Student’s t-
test, one-way analysis of variance (ANOVA) with post-hoc Bonferroni’s multiple 
comparison test, or two-way repeated measures ANOVA with post-hoc Bonferroni’s 
multiple comparison test, where best applicable.  Data are expressed and plotted as 
mean ± SEM.  A p value of < 0.05 was considered significant. 
 
3.1.3 RESULTS 
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Antibiotic administration.  Naïve mice were randomly divided into up to four possible 
treatment groups: antibiotic treatment, antibiotic treatment with exposure to non-
medicated animals or bedding, water treatment, or water treatment with exposure to 
medicated animals or bedding.  Ten separate experiments with groups of 3–8 mice were 
performed.  Antibiotics were administered by oral gavage in experimental cohorts 1–5 
and 9–10, and through the drinking water in cohorts 6–8.   
 
Referred cutaneous allodynia.  The behavior experimenter described any reaction of 
the mouse to each filament application instead of directly interpreting whether the 
behavior of a mouse should be considered a positive withdrawal response.  A total of 
sixteen possible behaviors were provided, ranging from no response to grooming to 
jumping.  In order to quantify the positive response rate, the baseline data from all 
experimental cohorts were combined (n = 121 mice, 1210 filament tests) to determine 
behaviors that were common in naïve animals, as these responses were considered 
unlikely to represent pain-related behavior.  The list was further refined by identifying 
those behaviors that were most compatible with the criteria suggested by Laird et al. 
(2001).  The remaining behaviors were interpreted as positive withdrawal responses: (a) 
sharp retraction of the abdomen; (b) jumping; (c) immediate scratching of the filament 
application site; or (d) immediate flailing of one or both hind feet.  The post hoc scoring 
metric was applied to the von Frey data from all experimental cohorts. 
 
In Cohort 1, there was a significant but transient increase in the response rate to 
abdominal von Frey filament application in antibiotic-treated animals (Figure 3-1).  This 
allodynia peaked five days after the cessation of antibiotic treatment (day 15), persisted 
at day 20, and was recovering at day 25.  Multiple attempts were made to repeat this 
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finding in separate experimental cohorts with antibiotics administered through oral 
gavage (Figure 3-1) or drinking water (Figure 3-2).  While the antibiotic-treated group 
occasionally trended toward a higher response rate than the control group, this 
difference was not statistically significant in any cohort.  A reliable antibiotic-induced 
visceral hypersensitivity model could not be established. 
 
In certain cohorts, antibiotic-treated mice were cohoused with control mice or provided 
with their soiled bedding.  This was done to evaluate whether exposure to normal fecal 
microflora would rescue antibiotic-induced visceral hypersensitivity, as had been 
reported with probiotic therapy (Verdú et al., 2006).  However, the inconsistency of 
behavior responses in antibiotic-treated animals precluded any meaningful interpretation 
on the impact of normal microflora exposure. 
 
Behavior response to intracolonic capsaicin.  In certain cohorts, visceral sensitivity 
was measured by quantifying the behavioral pain-related responses to the intracolonic 
instillation of capsaicin (Figure 3-3).  In Cohort 4, there was a significant attenuation in 
capsaicin-induced behaviors in mice treated with antibiotics as compared to controls.  
This attenuation was not apparent in any of the following cohorts.  The capsaicin dose 
was reduced in the later experiments in case differences between groups were being 
masked by a ceiling effect.  However, no significant differences were observed. 
 
The response rate to von Frey filament application to the abdomen was evaluated 
immediately before and following the intracolonic capsaicin test in two experimental 
cohorts (Figure 3-4 A).  No significant differences were observed.  The lack of 
demonstrable referred allodynia in any treatment group following intracolonic instillation 
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of capsaicin was concerning and prompted critique of the post hoc scoring metric used 
to define positive withdrawal responses.  Behavior data from water-treated control 
animals before and after capsaicin administration were compiled for each cohort.  Six 
behavior types were represented: arching the back, licking, recoiling from the filament, 
flailing one or both hind feet, jumping, or no observed response.  Of these, recoiling, 
flailing, and jumping qualified as positive withdrawal responses in the scoring metric.  In 
Cohort 5 (n = 3), only flailing of the hind feet was significantly increased from pre-
capsaicin values, and in Cohort 6 (n = 6), no behavior significantly changed following 
capsaicin administration (Figure 3-4 B).      
 
3.1.4 DISCUSSION 
 
In this study, we questioned whether antibiotic-induced dysbiosis and subsequent 
visceral hypersensitivity could be monitored non-invasively through evaluation of 
referred cutaneous allodynia.  Unfortunately, a reliable dysbiotic murine model of 
referred visceral pain could not be established.   
 
The inconsistent behavior responses observed between experimental cohorts may be 
related to different states of dysbiosis despite using a similar antibiotic treatment.  
Specific microbial changes are likely influenced by many factors, including the strain of 
mouse, the source of the animals, the basal composition of the gut microbiota, the dose 
of antibiotics administered, and the environmental conditions (Aguilera et al., 2015).  
Treatment may also favor the expansion of antibiotic-resistant bacterial groups, which 
may or may not be pathogenic.  In this study, all experiments utilized the same mouse 
strain from one commercial breeder and the antibiotic dose was kept consistent within 
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the delivery method.  However, the mice were housed under conventional, non-sterile 
conditions, and although cleaned between uses, the behavior testing equipment was 
utilized for other rodent experiments.  Characterization of the microbial changes within 
each cohort, including identification and quantification of the gut microbiota, went beyond 
the scope and expertise of this study.  However, fecal pellets from mice at baseline and 
after ten days of antibiotic treatment were provided to collaborators.  Their preliminary 
analysis revealed striking differences in the composition of the microflora after antibiotic 
treatment (T. Johnson, personal communication; data not shown).  However, the basal 
composition of the microflora and the resulting changes induced by antibiotic therapy 
were not consistent between cohorts.  Standardization of the basal microflora may be 
necessary to generate a predictable and reliable behavior model.  
 
A disconcerting finding was the lack of referred allodynia following intracolonic instillation 
of capsaicin, particularly in control (water-treated) animals.  The development of robust 
abdominal allodynia following the intracolonic administration of capsaicin (0.1% or 0.3%) 
in otherwise naïve animals has been repeatedly demonstrated in outbred Swiss mouse 
stocks, inbred mouse lines (including C57BL/6), and Sprague-Dawley rats (Laird et al., 
2001; Galan et al., 2003; Kawao et al., 2004; Pitcher et al., 2007; Sanoja et al., 2010; 
González-Cano et al., 2013; Pitcher et al., 2013).  Galan et al. (2003) also reported 
persistence of the referred allodynia, which was significant at all time points tested up to 
24 hours post-instillation.  Given a strong reaction to intracolonic capsaicin was evident 
in all treatment groups based on the number of pain-related behaviors observed over the 
20 minute testing window, it seems likely that the capsaicin preparation was effective.  
This suggests the failure to detect the expected abdominal referred allodynia was more 
likely due to a fault in the detection method than to an absence of the secondary effect.  
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This not only is concerning for the tests involving capsaicin, but in all the preceding work 
solely evaluating dysbiosis-induced referred cutaneous allodynia.  We considered 
several potential causes for the lack of success with the mechanical stimulation test. 
 
Filament bending force.  Laird et al. (2001) used von Frey filament application to the 
abdomen as a test of referred allodynia, and employed a series of five filaments with 
forces of 1, 4, 8, 16, and 32 mN (as in the Optihair2-Set, Marstock Nervtest, Germany).  
They found the responses to mechanical stimulation of the abdomen following 
intracolonic instillation of capsaicin (0.1 or 0.3%) were significantly increased from 
baseline at all bending forces tested.  Owing to differences in the sources of 
standardized sets of von Frey filaments, a filament with a bending force of 1 mN was not 
available.  The 3.22 filament has a target bending force of 0.16 g or 1.6 mN, and the 
2.83 filament has a target bending force of 0.07 g or 0.70 mN.  These filaments each 
approximate the lower end of the reported testing series.  Testing at a higher filament 
force could be considered. 
 
Filament calibration.  Von Frey filaments are subject to wear with repeated use.  Given 
the number of required stimuli and the duration of the experiments, it is possible the 
filaments in use became uncalibrated over time, leading to spurious results.  The 
bending force can be validated by advancing the filament carefully toward a sensitive 
balance, typically with the aid of a clamp or micromanipulator, and recording the output 
value.  If there is a discrepancy in the exerted force and the filament target force, 
replacement of the filaments may be necessary. 
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Positive withdrawal responses.  The determination of positive and negative responses to 
von Frey filament application was based on post hoc interpretation of observational 
behavior data.  The behaviors were categorized as nocifensive or innocuous based on 
similarities to the criteria provided by Laird et al. (2001) and likelihood of occurrence at 
baseline.  Only baseline data were included in the development of the scoring metric, 
since the experimenter performing the post hoc analysis was no longer blinded to the 
experimental manipulations.  Also, the behavior descriptions may have been over 
simplified.  For example, “licking” could refer to immediate attention to the filament 
application site, which would have been considered a positive response based on the 
published criteria, or to innocuous grooming behavior, which was common at baseline.  
Without the ability to distinguish these, “licking” was not considered a positive response.  
Ideally, baseline and experimental withdrawals should have been assessed directly at 
the time of testing. 
 
The attenuation of capsaicin-induced pain-related behaviors in antibiotic-treated mice in 
one cohort is reminiscent of the recent findings of Aguilera et al. (2015), where following 
a 2-week treatment of bacitracin, neomycin, and amphotericin B, capsaicin-induced 
pain-related behaviors were unexpectedly reduced by 48% as compared to vehicle-
treated control mice.  This significant reduction was attributed to downregulation of 
certain cannabinoid and opioid receptors in the gut and the possible generation of an 
analgesic-like state.  It is unclear whether this local neuro-immune response may also 
influence the likelihood of referred allodynia in this model.    
 
3.2.1 NOVEL UTILIZATION OF A FORELIMB GRIP FORCE ASSAY TO MONITOR 
ANTIBIOTIC-INDUCED VISCERAL HYPERSENSITIVITY IN MICE 
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Given the limited success in using standardized von Frey filaments to assess referred 
cutaneous allodynia, other non-invasive methods of monitoring visceral hypersensitivity 
were considered.  Stretch-induced discomfort, as measured by functional deficits in 
forelimb grip force, had been reported as a phenotype of deep tissue pain and chronic 
low back pain in mice (Kehl et al., 2000; Millecamps et al., 2011).  Inspired by these 
findings, we conducted a pilot study to evaluate whether antibiotic-induced visceral 
hypersensitivity could be monitored non-invasively through movement-evoked axial 
stretching and functional deficits in forelimb grip strength.  
 
3.2.2 METHODS 
 
Animals.  The experimental procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota.  Adult male C57BL/6 
mice (20–25g; Harlan Labs, Madison, Wisconsin USA) were maintained in a 
conventional vivarium with a 12:12 light/dark cycle (lights on at 07:00 h) and ambient 
temperature of 21±2°C.  The animals were socially housed in groups of four in 
transparent plastic cages with corncob bedding, compact cotton nesting material, and ad 
libitum access to water and standard rodent chow.  The mice were allowed to habituate 
for at least 3 days under these conditions before the start of experimental manipulations.   
   
Antibiotic administration.  Mice received a combination of non-absorbable antibiotics 
by oral gavage once daily for ten days, in accordance with the method described by 
Verdú and colleagues (2006).  Bacitracin and neomycin were diluted in sterile water 
(each to 4 mg/mL), with the addition of pimaricin (0.2 mg/mL) to prevent yeast 
overgrowth.  For the final five days, the antibiotic concentrations were reduced to 
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bacitracin 2 mg/mL, neomycin 2 mg/mL, and pimaricin 0.1 mg/mL.  Control animals 
received sterile water (vehicle).  The gavage volume was 100 µL per mouse.  To 
examine whether exposure to fecal pellets from mice without altered gut flora could 
protect against the antibiotic-induced changes in visceral sensitivity, select antibiotic-
treated mice in each cohort were cohoused with control mice.   
 
Functional deficits in grip strength.  Forelimb grip force was measured using a grip 
force analyzer (Bioseb, France).  During testing, the mouse was held by its tail and 
carefully passed in a rostral-to-caudal direction over a wire mesh grid connected to a 
force transducer.  The mouse was allowed to grip the grid using only the forepaws while 
steady horizontal pressure was applied via the tail to induce stretching.  The peak force 
exerted by the forelimbs when pulling on the grid was recorded by the force transducer.  
Five grip force measurements were obtained and averaged for each animal with a 
minimum 5-minute interval between tests. 
 
Statistical analysis.  Data were entered into a spreadsheet for analysis.  Statistical 
tests were performed using GraphPad Prism (version 5.0d, GraphPad Software, San 
Diego, California USA, www.graphpad.com).  Groups were compared by one-way 
analysis of variance (ANOVA) with post-hoc Bonferroni’s multiple comparison test.  Data 
are expressed and plotted as mean ± SEM.  A p value of < 0.05 was considered 
significant. 
 
3.2.3 RESULTS 
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Forelimb grip force was evaluated as a possible measure of discomfort induced by axial 
stretching.  In Cohort 9, the average forelimb grip force exerted by antibiotic-treated mice 
was significantly reduced compared to water-treated controls, but not significantly lower 
than the other groups.  This attenuation of grip force was also not evident in antibiotic-
treated mice cohoused with control mice.  No differences were observed between 
treatment groups in Cohort 10. 
 
3.2.4 DISCUSSION 
 
A novel behavior assessment employed to quantify visceral pain was forelimb grip force, 
as a functional deficit in grip may indicate discomfort induced by axial stretching.  
Diminished average grip force was evident in one antibiotic-treatment group.  However, 
a visceral pain phenotype was not confirmed in these mice by any other means.  The 
reduced willingness or capability to maintain grip is nonspecific and could represent 
fatigue or malaise due to other physiological processes such as dehydration or systemic 
inflammation.  This finding was also not repeated in the subsequent cohort, suggesting 
other confounding factors may be contributing to the reduced grip function.   
 
3.3.1 SEMI-QUANTITATIVE IMAGE ANALYSIS OF L6 DORSAL ROOT GANGLION 
SENSORY NEURONS IN A MURINE MODEL OF ANTIBIOTIC-INDUCED 
VISCERAL HYPERSENSITIVITY 
 
We hypothesized that VGF plays a functional role in modulating nociception and 
hypersensitivity in viscero-specific sensory neurons.  To explore this hypothesis, we 
utilized a mouse model originally developed to better understand the interplay between 
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visceral hypersensitivity and altered intestinal microbiota in IBS.  In the previous sections 
of this chapter, we questioned whether antibiotic-induced dysbiosis and subsequent 
visceral hypersensitivity could be monitored non-invasively.  In addition, we expected 
this visceral hypersensitivity to be associated with DRG sensory neuron upregulation of 
nociceptive neuropeptides including VGF. 
 
As a pilot study, tissues from the experimental cohort with a discriminatory behavioral 
phenotype, as revealed by the forelimb grip assay (Cohort 9), were selected for further 
evaluation.  Semi-quantitative image analysis was performed to determine whether VGF 
upregulation was evident in viscero-specific sensory neurons.  Previous work 
investigating the role of VGF-derived peptides focused solely on somatic sensory 
neurons (predominantly those of the sciatic nerve), and the neurobiological mechanisms 
of visceral pain differ from those involved in somatic pain. 
 
3.3.2 METHODS 
 
Tissue preparation.  Animals were terminally anesthetized with isoflurane and 
sacrificed by transcardial perfusion with a pre-wash of calcium-free Tyrode’s (in mM: 116 
NaCl, 5.4 KCl, 1.6 MgCl2•6H2O, 0.4 MgSO4•7H2O, 1.4 NaH2PO4, 5.6 glucose, and 26 
Na2HCO3), followed by modified Zamboni’s fixative (4% paraformaldehyde and 0.2% 
picric acid in 0.1 M phosphate buffer, pH 6.9).  Spinal cord, lumbar dorsal root ganglia 
(DRG), and descending colon were collected and incubated in 10% sucrose overnight at 
4°C.  Tissues were cryosectioned (14 µm) and thaw-mounted onto gelatin-coated slides. 
 
	   94 
Immunohistochemistry.  Tissue sections of the L6 DRG were incubated in blocking 
buffer (PBS containing 0.3% Triton X-100, 1% bovine serum albumin, and 1% normal 
donkey serum) at room temperature for 30 min, then incubated overnight at 4°C in 
primary antisera prepared using blocking buffer as diluent.  Primary antisera used were: 
guinea pig anti-transient receptor potential vanilloid 1 (TRPV1), 1:500 (ref. Guo et al., 
1999), rabbit anti-calcitonin gene related peptide (CGRP), 1:1000 (24112; ImmunoStar, 
Hudson, Wisconsin USA), protein A-purified guinea pig anti-VGF, 1:1000 (ref. Riedl et 
al., 2009), and rabbit anti-substance P (SP), 1:1000 (Neuromics, Edina, Minnesota 
USA).  After rinsing with PBS, sections were incubated with appropriate combinations of 
cyanine-dye conjugated secondary antisera (Jackson ImmunoResearch, West Grove, 
Pennsylvania USA) for one hour at room temperature.  Sections were rinsed again in 
PBS, then incubated with NeuroTrace® 435/355 Blue (Molecular Probes, Inc., Eugene, 
Oregon USA) per manufacturer’s instructions.  The slides were coverslipped using 
glycerol and PBS containing 0.1% p-phenylenediamine (Sigma Chemical Co., St. Louis, 
Missouri USA).  Images were collected using an Olympus FluoView1000 confocal 
imaging system, analyzed using ImageJ (National Institutes of Health), and processed 
for publication using Adobe Photoshop.   
 
Cell counting.  DRG were mounted and sectioned parallel to the nerve root axis.  At 
least three equally spaced sections from each DRG separated by a minimum distance of 
56 µm were selected for image collection.  The region of interest for imaging was 
visualized on the NeuroTrace channel, and the entire neuron population was imaged as 
best possible with non-overlapping fields, resulting in an average of 5 images per 
animal.  Neuron cell body size and intensity of fluorescence were analyzed in ImageJ, 
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using the Nissl-like NeuroTrace labeling to manually outline cell margins.  Only cells with 
a visible nucleus were counted.     
 
Image analysis.  Semi-quantitative image analysis was conducted as described in detail 
in Chapter 4.  Briefly, double-labeled fluorescent tissue sections were imaged to produce 
a separate 8-bit greyscale image for each color channel.  The red (cyanine-3) and green 
(cyanine-2) channels were used for markers of experimental interest, while the blue 
channel was exclusively used for Nissl-like NeuroTrace labeling.  All images from a 
specific antibody marker and within a particular color channel were compiled into a stack 
in ImageJ.  The image stack was then binarized using the Auto Threshold ImageJ plugin 
(version 1.15, Landini G, fiji.sc/Auto_Threshold) using the stack histogram, which would 
include images from control and experimental animals.  Splitting the stack back into 
individual images, each binarized version was saved with the original greyscale images.   
 
For cell counting, images of the identical microscope field were compiled into stacks of 
seven images: greyscale blue, greyscale red, binarized red, greyscale green, and 
binarized green.  Manual cell outlining was conducted in the blue (NeuroTrace) channel, 
and the mean grey value (MGV) and cross-sectional area were simultaneously 
measured for the outlined region of interest for all images in the stack.  A cell was 
considered negative for a particular marker if the mean grey value of the binarized 
channel was 0 (all pixels black).  To determine which cells had sufficient fluorescent 
intensity to be considered positive, the average greyscale MGV for the negative 
population of cells was calculated.  The threshold to be considered positive was 
determined as 3 standard deviations above the average for the negative population. 
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Statistical analysis.  Data were entered into a spreadsheet for analysis.  Statistical 
tests were performed using GraphPad Prism (version 5.0d, GraphPad Software, San 
Diego, California USA, www.graphpad.com).  Groups were compared by Student’s t-
test.  Data are expressed and plotted as mean ± SEM.  A p value of < 0.05 was 
considered significant. 
 
3.3.3 RESULTS 
 
Semi-quantitative image analysis was performed on labeled sections from the sixth 
lumbar (L6) DRG (Figure 3-6).  All sections were derived from the same embedded 
tissue block.  Cell counting was performed by a different investigator for each slide set in 
a blinded manner; all analysis was performed by one investigator.  Two animals were 
ultimately excluded due to poor tissue section quality and/or insufficient (< 100) neurons 
available for analysis, one from the antibiotic-treatment group and one from the water-
treatment group, reducing each group to three animals.  The total number of neurons 
counted per animal was 611 ± 57.  A cross-sectional area cutoff of 380 µm2, which is 
equivalent to a calculated cell diameter of 22 µm, was selected as the cutoff for 
categorization of neurons by size based on the appearance of the neuron size histogram 
(Figure 3-7). 
 
Antibiotic treatment was associated with increased sensory neuron immunoreactivity (-ir) 
to SP (22.4 ± 1.9% of all neurons vs. 9.4 ± 0.8%, p < 0.01) and VGF (18.4 ± 1.8% vs. 9.4 
± 2.7%, p < 0.05) as compared to water-treated controls (Figure 3-8 A).  There was no 
significant difference between groups in CGRP-ir (25.3 ± 2.6% vs. 18.6 ± 1.4%) or 
TRPV1-ir (28.2 ± 1.3% vs. 26.5 ± 3.0%).  Size distribution analysis revealed these 
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changes predominated in small (≤ 380 µm2) sensory neurons (Figure 3-8 B-E).  
Interestingly, significant upregulation of CGRP was evident within small but not medium-
to-large sensory neurons (Figure 3-8 B).   
 
Colocalization analysis was performed within double-labeled slide sets.  While there was 
no significant difference in the overall number of cells with immunoreactivity to CGRP 
and TRPV1, there was a small but significant increase in the percentage of TRPV1-ir 
cells also expressing CGRP in antibiotic-treated animals (Figure 3-9 A).  The number of 
neurons immunoreactive to SP and VGF more than doubled in antibiotic-treated animals 
(5.0 ± 0.4% of all neurons vs. 2.1 ± 0.3%, p < 0.01).  The proportion of SP-ir neurons 
also expressing VGF and vice versa did not change (Figure 3-9 B). 
 
To further evaluate the neuron populations positive for SP and/or VGF, the image data 
from the two experimental groups were pooled and frequency histograms were 
generated (Figure 3-10).  As expected, neurons with SP-ir were predominately within the 
peak of “small” neurons, with an average cross-sectional area of 258 ± 5.9 µm2 in 
antibiotic-treated animals and 301 ± 10.1 µm2 in water-treated controls.  VGF-positive 
neurons were more broadly distributed, with an average cross-sectional area of 395 ± 
11.6 µm2 in antibiotic-treated animals and 435 ± 16.6 µm2 in water-treated controls.  As 
observed with the previous analysis, colocalization between the two markers was 
limited.   
 
3.3.4 DISCUSSION 
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Sensory innervation from the descending colon follows two anatomic pathways, the 
lumbar splanchnic nerves and the paired pelvic nerves, which terminate in the 
thoracolumbar and lumbosacral spinal cord, respectively (Brierley et al., 2004).  This is 
consistent with the bimodal distribution of labeled sensory neurons identified by 
retrograde labeling of the mouse descending colon, encompassing DRG levels T8-L1 
and L6-S1 (Robinson et al., 2004).  For this pilot study, we focused on the L6 DRG 
based on our previous work that identified an association between L6 sensory neuron 
transduction and anterograde labeling of fibers in the segment of descending colon just 
proximal to the pelvic inlet (Schuster et al., 2013).  However, sensory neurons in the L6 
DRG innervate several pelvic organs via the pelvic nerve, including the descending 
colon, urinary bladder, prostate, vagina, and cervix (Inskip et al., 2009; McCarthy CJ et 
al., 2015).  Based on the experimental model, observed changes in the L6 sensory 
neurons are most likely attributable to disturbances in the colon; however, in future work 
the possibility of concomitant disease in other pelvic organs (e.g. urocystitis) should be 
excluded.  Examination of the thoracolumbar DRG (T8-L1) may also be warranted, as 
sensory neurons of these DRG innervate the descending colon as well as the 
dermatomes of the ventral abdominal region tested for cutaneous referred allodynia 
(Patestas and Gartner, 2006). 
 
Primary afferent neurons are divided into subclasses based on distinct morphological 
and molecular features.  In general, the myelinated afferent fibers of medium-size type 
Aβ and large-size type Aα are responsible for innocuous tactile sensation and 
proprioception, while smaller myelinated Aδ and unmyelinated C-fibers carry thermal 
and nociceptive input (Lawson and Waddell, 1991; Patestas and Gartner, 2006).  While 
there is some overlap in the size ranges, most small-diameter sensory neurons are 
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nociceptive.  In this study, significant neuropeptide upregulation in antibiotic-treated 
animals as determined by immunohistochemistry was limited to small sensory neurons.  
While only non-specific behavior was observed with this cohort (discussed in 3.2.4), 
increased activity of nociceptive neurons suggests a pain-related phenotype may exist 
provided an appropriate detection method is utilized. 
 
Small-diameter nociceptive sensory neurons can be divided into two major 
neurochemical subtypes that also differ anatomically in the region of termination in the 
dorsal horn of the spinal cord.  Peptidergic neurons contain neuropeptides such as 
calcitonin-gene related peptide (CGRP) and substance P (SP), express the TrkA 
receptor, and project to lamina I and outer lamina II.  Non-peptidergic neurons lack 
peptides but bind the plant lectin isolectin B4 (IB4), express the P2X3 receptor, and 
terminate predominantly in inner lamina II (Stucky and Lewin, 1999).  Interestingly, 
TRPV1 receptors are restricted to peptidergic fibers in mice but not rats (Zwick et al., 
2002).      
 
Putative antibiotic-induced dysbiosis was associated with upregulation of CGRP, SP, 
and VGF in predominantly small-diameter sensory neurons.  In neuropathic pain models 
and DRG neuron culture, VGF-derived peptides have been shown colocalized with SP, 
CGRP, TrkA, and P2X3 (Rizzi et al., 2008; Riedl et al., 2009).  In this study, VGF 
expression was observed throughout the range of neuron sizes and colocalization with 
SP was limited (< 30%).  This finding suggests the experimental condition is associated 
with upregulation of this VGF-derived peptide in nonpeptidergic C-fiber nociceptors and 
potentially in medium-sized Aδ or Aβ fibers as well, which are all associated with 
carrying afferent nociceptive information from the viscera (Patestas and Gartner, 2006).  
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The role of VGF in this context is unclear, and further investigation is warranted to better 
elucidate the involvement of VGF in visceral pain. 
 
Increased protein expression levels of TRPV1 in sensory neurons have been reported 
for pathological pain conditions (Vilceanu et al., 2010), most notably in human biopsy 
specimens from patients with inflammatory bowel disease (Yiangou et al., 2001).  In this 
study, sensory neuron expression levels of TRPV1 were not changed in antibiotic-
treated animals.  The TRPV1 channel is activated by capsaicin, heat, protons, and 
endovanilloids.  The lack of TRPV1 upregulation in animals with putative antibiotic-
induced dysbiosis may help explain the congruity in spontaneous, capsaicin-induced 
behaviors between antibiotic- and water-treated animals (discussed in 3.1.4). 
 
CONCLUSIONS 
 
Antibiotic-induced dysbiosis was not reliably associated with referred cutaneous 
allodynia of the abdomen in mice.  However, the inconclusive results of the abdominal 
mechanical stimulation assay were complicated by the need to perform post hoc 
interpretation, and the method requires refinement.  The only behavior assay with 
promising results was the functional deficit in forelimb grip force, which at best is 
nonspecific.  Other factors likely contributed to the lack of reliable behavioral phenotype 
in the dysbiotic model, including variability in the basal gut microflora, potential for 
secondary infectious processes, and the lack of TRPV1 upregulation in viscero-specific 
sensory neurons, which likely influenced the results of capsaicin-induced behavior 
assays.  Thorough characterization of the microbial changes, including evaluation for 
pathogenic overgrowth, would complement and inform future work.  
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Antibiotic treatment and presumed dysbiosis were associated with upregulation of 
CGRP, SP, and VGF in predominantly small-diameter sensory neurons of the sixth 
lumbar DRG.  VGF expression was observed throughout the range of neuron sizes and 
colocalization with SP was limited, suggesting a role for VGF beyond peptidergic 
sensory neurons.  Increased expression of nociceptive neuropeptides supports the 
potential utility of this experimental model for assessing visceral hypersensitivity, 
provided an appropriate behavioral assay is identified.  As TRPV1 expression was 
unchanged following antibiotic treatment, the value in antemortem testing with capsaicin 
is unclear.   
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1, The frequency of positive withdrawal responses to von Frey filament 
application to the abdomen in mice treated by oral gavage.  Group sizes in each cohort 
are specified.  The grey shaded region indicates the 10 days of antibiotic treatment.  In 
Cohort 1, the response rate of antibiotic-treated animals was significantly higher than 
water-treated controls on days 15 and 20 (two-way ANOVA with multiple comparisons, * 
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p < 0.05, ** p < 0.01).  In Cohort 4, the response rate of antibiotic-treated animals 
trended higher but was not statistically significant at any time point. 
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Figure 3-2, The frequency of positive withdrawal responses to von Frey filament 
application to the abdomen in mice treated via the drinking water.  Group sizes in each 
cohort are specified.  The grey shaded region indicates the 7 days of antibiotic 
treatment.  The response rate between antibiotic-treated and water-treated animals was 
not statistically significant at any time point. 
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Figure 3-3, Spontaneous behaviors following intracolonic (IC) instillation of capsaicin in 
antibiotic-treated (ATB) and water-treated animals.  Each symbol represents an 
individual animal.  The timing of testing is as follows: Cohort 4 = day 46; Cohort 5 = day 
30; Cohort 6 = day 28; and Cohort 7 = day 15.  In Cohort 4, antibiotic treatment was 
associated with a significant attenuation in capsaicin-induced behaviors (unpaired two-
tailed t-test, ** p < 0.01).  This attenuation was not evident in any other cohort. 
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Figure 3-4, (A) Response rate to abdominal von Frey filament application before and 30 
minutes after intracolonic (IC) instillation of capsaicin (white and shaded bars, 
respectively).  Withdrawal responses were more frequent in animals following capsaicin 
administration in Cohort 5, but these trends were not significant in any treatment group.  
There were no significant differences in Cohort 6.  (B) Response behaviors were re-
evaluated in water-treated control animals from Cohort 5 (n = 3) and Cohort 6 (n = 6).  
Of the six possible responses recorded for animals before and after capsaicin treatment, 
a significant difference was only evident for one behavior type in Cohort 5 (paired two-
tailed t-test, * p < 0.05).  However, this difference was not observed in the subsequent 
cohort.           
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Figure 3-5, Forelimb grip force in animals treated by oral gavage.  In both cohorts, 
testing occurred on day 11.  Each symbol represents an individual animal.  In Cohort 9, 
the average forelimb grip force was significantly reduced in antibiotic-treated mice as 
compared to water-treated controls (one-way ANOVA with multiple comparisons, * p < 
0.05).  This effect was not evident in the subsequent experimental cohort.        
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Figure 3-6, Representative pseudocolored immunofluorescence photomicrographs of 
mouse L6 DRG.  (A-H) Double-immunofluorescence staining of sensory neurons 
expressing CGRP-ir (green) and TRPV1-ir (magenta).  Occasional CGRP-positive cells 
also displayed positivity for TRPV1 (white in merge pictures, D and H).  (I-P) Double-
immunofluorescence staining of sensory neurons expressing SP-ir (green) and VGF-ir 
(magenta).  Increased fluorescence intensity was apparent in antibiotic-treated animals.  
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Colocalization of SP and VGF was also increasingly evident (white in merge pictures, L 
and P).  Scale bar = 100 µm.    
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Figure 3-7, Frequency distributions of the cross-sectional area of quantified sensory 
neurons from L6 DRG sections.  Double labeling was based on pairing primary 
antibodies raised in two different species, and equivalent slide sets were utilized.  There 
were no significant differences in the cell size frequency distributions between the 
double-labeled slide sets (A and B) or between tissues from antibiotic-treated (solid line, 
grey shading) or control animals (dashed line) within slide sets.  The vertical dotted line 
shows the cut-off used to categorize neurons as small (≤ 380 µm2) or medium to large 
(>380 µm2), and corresponds to a calculated cell diameter of 22 µm. 
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Figure 3-8, Quantification of double-immunofluorescence staining of L6 DRG sensory 
neurons expressing CGRP and TRPV1 or SP and VGF.  (A) Antibiotic treatment was 
associated with significantly increased numbers of neurons immunoreactive to SP and 
VGF as compared to water-treated controls.  (B) Size distribution analysis revealed a 
significant increase in CGRP-positive neurons in antibiotic-treated animals in small 
(<380 µm2) neurons.  (C) TRPV1 was not statistically changed in either neuron size 
category.  (D) SP predominated in small sensory neurons and was significantly 
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increased following antibiotic treatment, while (E) VGF was evident in neurons of various 
size; (unpaired two-tailed t-test, * p < 0.05, ** p < 0.01). 
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Figure 3-9, The percent colocalization between (A) CGRP and TRPV1 and (B) SP and 
VGF is shown for antibiotic- and water-treated mice.  There was a significant increase in 
the percentage of TRPV1-ir neurons also expressing CGRP following antibiotic-
treatment; (unpaired two-tailed t-test, * p < 0.05). 
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Figure 3-10, Stacked frequency distributions of the combined neuron counts of all 
animals within each group.  The vertical dotted line approximately shows the cut-off used 
to categorize neurons as small or medium to large (380 µm2).  (A-C) In water-treated 
animals, low numbers of neurons were positive for SP (blue) or VGF (yellow).  (D-F) In 
antibiotic-treated animals, the number of neurons positive for SP and/or VGF 
significantly increased.  (E) SP immunoreactivity predominated in small sensory 
neurons, while (F) the VGF-derived peptide increased in small- to medium-sized 
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neurons.  The proportion of sensory neurons with colocalization of SP and VGF (green) 
remained proportional. 
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Chapter 4 
 
 
Refinement of methods 
 
 
Use of binarization in semi-quantitative image analysis  
to clarify immunofluorescence positive cutoff values  
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SUMMARY 
 
A valuable tool in distinguishing sensory neuron subpopulations is the use of 
fluorescence microscopy.  However, image analysis is needed to provide numerical data 
for statistically comparing fluorescence intensity.  Distinguishing what shade of grey 
should be the cutoff between positive and negative is challenging and potentially subject 
to bias.  To clarify immunofluorescence positive cutoff values for 8-bit images, we sought 
to develop an inexpensive, reliable, and adaptable method using only readily available 
software and techniques.  Through the use of binarized images, the parameters of the 
negative cell population could be clearly defined and used to mathematically calculate 
an appropriate cutoff value.  This approach takes advantage of automated processes in 
ImageJ and Microsoft Excel to expedite analysis, and can be applied to entire sets or to 
specific subsets of images.  Currently, the main drawback of this method is the time 
investment necessary to create and apply the binarized images; however, it seems likely 
that this process could also be automated with appropriate macro coding.      
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INTRODUCTION 
 
The neuron cell bodies in the DRG represent a heterogeneous population of neurons 
that convey sensory information from the periphery to the central nervous system.  
These primary afferent neurons are commonly classified by morphological and 
neurochemical signatures.  A valuable tool in distinguishing sensory neuron 
subpopulations is the use of fluorescence microscopy, where fluorophore-labeled 
markers and stains are employed to locate interesting features.  However, simply stating 
that the fluorescence appears brighter for a particular cell or treatment group is 
insufficient.  Image analysis is needed to provide numerical data for statistically 
comparing fluorescence intensity.   
 
The smallest units comprising a digital image are pixels.  Each pixel in a fluorescence 
micrograph is a measurement of the light emitted by the sample from that point in space 
(Bankhead, 2014).  In an 8-bit greyscale image, the intensity of each pixel is derived 
from a palette of 256 possible shades of grey, ranging from black to white.  The pixel 
values are represented as integers, with values from 0 (black) to 255 (white).  Ideally, a 
histogram of the grey values from a fluorescence image would reveal two distinct 
clusters: positive pixels from where the sample was emitting light (white) and negative 
pixels lacking fluorescence (black).  In practice, this bimodal distribution is often merged, 
and distinguishing what shade of grey should be the cutoff between positive and 
negative is challenging and potentially subject to bias.  While dedicated systems have 
been designed for image analysis in fluorescence immunohistochemistry, many require 
expensive software and hardware for image acquisition, analysis, and storage (Jensen, 
2013). 
	   119 
 
Reviewing the scientific literature for inexpensive and reliable alternatives for image 
analysis became unrewarding, as most publications fail to disclose the exact image 
processing and analyses performed.  One of the more commonly cited methods for 
sensory neuron image analysis was the approach of Fang and colleagues (2006), 
whereby the numeric intensity values for the sampled cell profiles were normalized to the 
brightest and dimmest intensity values in the same section or DRG.  These relative 
immunointensity values were correlated to subjective scores to establish the cutoff 
between positive and negative, which in their case was 20% intensity.  While the 
calculations required for this method are easily employed, application of this method was 
generally unsatisfying.  Normalization of the data does nothing to affect the distribution 
of the intensity values other than change the units from an integer value to a percentage, 
and the cutoff value is still entirely subjective. 
 
Semi-quantitative immunohistochemical analysis frequently takes advantage of ImageJ, 
a Java image processing and analysis program developed by Wayne Rasband and 
made available in the public domain through the National Institutes of Health 
(http://imagej.nih.gov/ij/docs/index.html).  A multitude of free add-ons that extend the 
core functionality are also available from various sources.  ImageJ can be readily 
employed to measure intensity values in manually-drawn regions of interest, as needed 
in analyzing the heterogeneous neuron populations in DRG.  However, ImageJ can also 
be used for segmenting images into objects of interest – in this case, areas of 
fluorescence – from the background.  In the resulting binary image, each pixel can only 
have one of two values, black or white.  The binarized image is generated by identifying 
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pixels above or below a particular threshold value, which can be calculated from image 
histograms or manually applied.     
 
As using ImageJ to define segmented regions is likely to be faster, more reproducible, 
and less biased, we developed a method utilizing binarized images to clarify 
immunofluorescence positive cutoff values in semi-quantitative image analysis of DRG 
sensory neurons.          
 
IMAGE ANALYSIS WITH BINARIZATION 
 
Image acquisition.  Slide-mounted tissue sections of rat or mouse DRG were 
sequentially incubated with primary antisera, appropriate combinations of cyanine-dye 
conjugated secondary antisera, and NeuroTrace® 435/355 Blue Nissl stain (Molecular 
Probes, Inc., Eugene, Oregon USA), as discussed in detail in earlier chapters.  The 
slides were coverslipped using glycerol and PBS containing 0.1% p-phenylenediamine 
(Sigma Chemical Co., St. Louis, Missouri USA).   
 
Images were collected using an Olympus FluoView1000 confocal imaging system.  
Acquisition settings were determined for each color detection channel using the range 
finder look-up table, where blue pixels represent zero intensity and red pixels represent 
saturated intensity.  The parameters were set so there was no oversaturation in areas of 
intense fluorescence and offset so the background intensity measured just above zero 
(Brown, 2007).  The same image acquisition settings were maintained across the slide 
set and used for experimental and control tissues.  The region of interest for imaging 
was visualized on the NeuroTrace channel, and the entire neuron population was 
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imaged as best possible with non-overlapping fields.  Tissue sections were imaged to 
produce a separate 8-bit greyscale image for each color detection channel per field.  In 
our hands, the red (cyanine-3, Cy3), green (cyanine-2, Cy2), and far-red (cyanine-5, 
Cy5) channels were used for markers of experimental interest, while the blue channel 
was used for Nissl-like NeuroTrace labeling.  To allow the cell counting to be performed 
by a blinded investigator, each image set was numbered sequentially and a separate 
index was maintained to identify the animal number and group.   
 
Image binarization.  All greyscale images from a specific antibody label and within a 
particular color detection channel were compiled into a stack in ImageJ (National 
Institutes of Health).  The image stack was then binarized (i.e. segmented into black and 
white) using the Auto Threshold ImageJ plugin (version 1.15, Landini G, 
fiji.sc/Auto_Threshold), which includes sixteen histogram-derived thresholding algorithm 
options.  The threshold was computed based on the stack histogram, allowing data from 
both control and experimental animals to be considered concurrently, and was applied to 
all slices in the stack.  Given that the stack histogram was typically comprised of a 
maximum peak near the right end of the histogram with a skew toward the left, the 
Triangle algorithm derived from the methods of Zack et al. (1977) often best segmented 
the data.  Splitting the stack back into individual images, each binarized version was 
saved alongside the original greyscale images (Figure 4-1).   
 
Cell counting.  Images of the identical microscope field were compiled into stacks of 
three to seven images in ImageJ, depending on the number of detection channels 
utilized: greyscale blue (Nissl staining), greyscale red, and binarized red, with the 
addition of the greyscale and binarized versions of green and far-red as needed.  
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Manual cell outlining was conducted using the NeuroTrace image, and only cells with a 
visible nucleus were counted.  The area and the mean grey value (MGV; the sum of the 
grey values of all the pixels in the selection divided by the number of pixels) were 
simultaneously measured for the outlined region of interest for all images in the stack 
(Figure 4-2 and Table 4-1).   
 
Data analysis.  The data values generated in ImageJ were exported to Microsoft Excel 
(Mac 2011 version 14.1.0, Microsoft Corporation) for analysis.  A typical spreadsheet 
was composed of at least five columns: image number, cell area, and the MGV of the 
NeuroTrace, greyscale, and binarized slices.  The data in each row represented an 
individual cell, and the data from all images within the same slide set were compiled.  
When blinding was no longer necessary, columns for the animal number and 
experimental groups were added, and the VLOOKUP function was utilized to efficiently 
translate the information from the image number index (entered into a separate 
worksheet). 
 
For each experimental marker, a cell had two values: the MGV of the original 
fluorescence image and the MGV of the binarized image.  Grey values of an 8-bit image 
range from 0 (black) to 255 (white).  Ideally, the MGV of the fluorescence image would 
reveal two distinct neuron populations: positive cells with fluorescence (white) and 
negative cells lacking fluorescence (black).  In practice, this bimodal distribution was 
often merged (Figure 4-3 A), and distinguishing the populations was challenging.  What 
shade of grey was the appropriate cutoff between positive and negative?  This problem 
was not directly resolved by the use of binarized images, as labels with patchy or 
granular immunoreactivity patterns still generated a mixture of black and white pixels.   
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The value in binarized images was not in revealing which cells were positive, but in 
clearly identifying which cells were negative.  A cell was considered negative for a 
particular marker if the MGV of the binarized channel was 0 (all pixels black).  The 
greyscale MGV of negative cells in the red (Cy3) and green (Cy2) channels typically 
followed a normal distribution (Figure 4-3 B).  It was not uncommon for the negative 
distribution to be slightly skewed in the far-red (Cy5) channel, possibly due to higher 
background fluorescence with this detection modality.   
 
By defining the parameters of the negative cell population, the criteria necessary for a 
cell to be considered positive could be established.  Calculation of the mean and 
standard deviation of the greyscale MGV of the negative cells was expedited by the use 
of array formulas, which work with a series of data values.  For example, consider a data 
table with values for 100 cells (rows 2 to 101), with the binarized MGV in column B and 
the greyscale MGV in column C.  The mean greyscale MGV of the negative cells could 
be calculated by: 
 
=AVERAGE(IF((B2:B101=0),C2:C101)) 
 
where values from column C (greyscale MGV) are averaged as long as the 
corresponding value in column B (binarized MGV) is equal to 0.  It should be noted that 
array formulas are finished by holding the CTRL and SHIFT keys while pressing Enter; 
simply pressing Enter will yield spurious results.      
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The cutoff to consider a cell positive was defined as 3 standard deviations above the 
average greyscale MGV of the negative cells of the entire slide set for that particular 
immune marker and detection channel.  This cutoff was universally applied to control 
and experimental animals alike. 
 
Generating counts of the number of positive cells for a particular animal was facilitated 
by array formulas.  Considering the previous hypothetical data set with binarized MGV 
data in column B, greyscale MGV data in column C, and the addition of animal 
identification numbers in column D, the count of positive cells for an individual could be 
calculated by: 
 
=SUMPRODUCT((B2:B101>0)*(C2:C101>[cutoff])*(D2:D101=”ID”)) 
 
which will return the number of neurons with a binarized MGV greater than 0 (non-
negative), greyscale MGV greater than the calculated cutoff (positive), and with the 
specific animal identification.  The total number of cells per animal can be determined 
through simpler means, such as the COUNTIF function. 
 
DISCUSSION 
 
This method of determining the positive cutoff value for 8-bit immunofluorescence 
images relies on histogram-derived algorithms and mathematical calculations using only 
readily available software.  The approach can be applied to entire sets or to specific 
subsets of images.  The binarized images are solely used to define the negative cell 
population; however, it may be possible to utilize the positive pixel data to establish other 
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cutoff parameters (e.g. determine whether a certain percentage of pixels being above 
threshold is informative).  The method has been successfully utilized in discriminating 
populations of cells with various cytoplasmic markers, ranging from granular to patchy to 
diffuse.  It is not known if it would work with purely membranous patterns (Cheuk and 
Chan, 2004), as the labeling of the periphery may not be sampled as cleanly with the 
manual cell outlining necessary in sensory neuron quantification.   
 
The cutoff was set at 3 standard deviations above the mean of the negative population.  
A cutoff was still utilized as fluorescent signal noise could potentially “contaminate” a 
binarized cell, resulting in a non-zero MGV in a cell that would not otherwise be viewed 
as positive (as seen in the Cy3 channel of Neuron 3 in Figure 4-2).  The choice in 
number of standard deviations was based on the conservative three-sigma rule-of-
thumb, whereby data values falling more than 3 standard deviations from the mean of 
the negative population are likely outliers, in this case representing the other (positive) 
population (Nikulin, 2001).       
 
Occasionally, when all images from a color detection channel were compiled, slide-to-
slide variability in fluorescence intensity became evident.  This variability precluded 
applying the same threshold to all images.  However, this was easily remedied by 
considering each group of images from a particular slide separately.  For this reason, it 
may be prudent to ensure control and experimental tissues are imaged from each slide. 
 
The main drawback of this method is the time investment necessary to create the 
binarized images.  When using more than one detection channel, the imaging system 
software creates a folder for each imaged field with separate images typically labeled as 
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“ImageNumber_C001” for the first channel, “ImageNumber_C002” for channel two, and 
so on.  To create the image stack in ImageJ, copies of all images for a particular channel 
need to be sorted into a single folder (e.g. Folder C001).  After the stack has been 
imported, thresholded, and split back into individual images, these images need to be 
saved and resorted back into their respective image number folders.  Depending on the 
number of animals and species-related size differences in the DRG, complete imaging 
for a single DRG in a study may require at least 40 but often well over 100 images.  
Sorting of images back and forth is tedious and requires attentive naming conventions to 
ensure the original greyscale data is not lost.  However, it seems likely that this process 
could be automated with appropriate macro coding.   
 
While relying predominantly on mathematically-derived cutoffs to categorize cells as 
positive or negative, a subjective component could not be entirely eliminated.  
Segmenting the images into black and white was performed using an automated 
thresholding function, but the choice of algorithm and determination whether the 
threshold level was appropriate still relied on visual inspection.   
 
CONCLUSIONS 
 
The inclusion of binarized image values in semi-quantitative image analysis of DRG 
sensory neurons provides the necessary information to clearly define to parameters of 
the negative cell population and to objectively calculate the positive immunofluorescence 
cutoff value.  The method utilizes only readily available software and is inexpensive, 
reliable, and adaptable.  Currently, the main drawback of this method is the time 
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investment necessary to create and apply the binarized images; however, it seems likely 
that this process could also be automated to further expedite analysis.     
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1, Representative immunofluorescence photomicrograph of a mouse DRG, 
showing (A) the original 8-bit greyscale image and (B) the resulting binarized black and 
white image.  
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Figure 4-2, Counting of DRG sensory neurons.  (A) Three cells were manually outlined 
and numbered for reference in Table 4-1, as shown in the layer mask.  An ImageJ stack 
would be composed of the following slices: (B) NeuroTrace, (C, E) the original greyscale 
images of the other detection channels, and (D, F) the binarized images of the other 
detection images.  Based on the binarized images, Neuron 1 is likely positive for Cy3 
and negative for Cy2.  Neuron 2 is negative in both channels.  Neuron 3 is likely positive 
for Cy2 and negative for Cy3, although there are a few white pixels in the binarized cell.  
(G) An ImageJ stack is a set of related images or layers (slices) displayed in a single 
window.  Only one slice is active at any one time.  Manual cell outlining is performed on 
the top slice (NeuroTrace) to define a region of interest.  By aligning the images in a 
stack, the MGV can be measured in the same region of interest in each slice 
simultaneously.   
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  Mean Grey Value 
Neuron Area (µm2) Cy2 Cy2 Bin Cy3 Cy3 Bin 
1 809.8 71.52 0 162.85 145.71 
2 461.2 63.98 0 58.70 0 
3 543.0 152.84 123.15 69.59 2.17 
 
 
Table 4-1, The area and mean grey values (MGV) for the three representative neurons 
shown in Figure 4-2.  Neuron 1 (yellow) is likely positive on the Cy3 channel but negative 
for Cy2.  Neuron 2 (blue) is negative for both markers, as evidenced by the completely 
black (0) binarized versions.  Neuron 3 (orange) is likely positive for Cy2 and negative 
for Cy3.  The non-zero value for the binarized Cy3 results from the few scattered positive 
pixels, which appear insufficient to otherwise consider the neuron positive.  The MGV of 
the NeuroTrace channel is not informative and therefore not shown.   
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Figure 4-3, Representative frequency distributions of sensory neuron MGV from two 
detection channels.  (A) The bimodal distribution of positive and negative neurons was 
often merged into a single skewed peak.  (B) Stacked frequency distributions show the 
distribution of negative cells (white) typically followed a normal distribution for Cy3 (and 
Cy2, not shown) and often a slightly skewed distribution for Cy5.  The cutoff to consider 
a cell positive (green) was defined as 3 standard deviations above the average 
greyscale MGV of the negative cells.  Depending on the thresholding method and the 
amount of noise in the image, variable numbers of cells were considered ambiguous 
(black).  These unknowns displayed positive pixels in the binarized image, but had an 
otherwise insufficiently high MGV to be considered positive.   
 
 
 
	   132 
Chapter 4 
 
 
Refinement of methods 
 
 
Critical examination of the simplified up-down (SUDO) 
method of mechanical sensitivity assessment 
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SUMMARY 
 
Mechanosensitivity is commonly assayed in animal models utilized in pain research.  
While frequently used to assess paw withdrawal thresholds, the classical up-down 
method of von Frey filament presentation is time-consuming and often inconsistent in the 
number of stimuli per animal.  The simplified up-down (SUDO) method was recently 
reported as a reliable, efficient, user-friendly modification that provides greater 
standardization; however, the provided statistical justification was inadequate for 
comparing the two methods.  We sought to validate the SUDO method for potential 
future use by investigating the agreement between the original and new methods and 
determining whether usable threshold estimates could be derived from retrospective 
data from mice and rats using the SUDO approach.  The limits of agreement (-1.3 and 
1.2 filament steps) did not preclude the SUDO method being used in place of the original 
method when assessing models of nerve injury-induced hypersensitivity, but may be too 
broad for other experimental applications.  Further work is needed to ascertain whether 
the proposed standardization of the testing experience reduces intra-subject variability in 
threshold values. 
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INTRODUCTION 
 
A commonly used assay for testing mechanical sensitivity involves the application of a 
von Frey fiber to a convenient body part, such as the hind paw, in an attempt to evoke a 
behavioral response.  While various paradigms on the use of von Frey filaments have 
been described, the most widely applied in pain research is the up-down method of 
Dixon (Dixon, 1980) as applied to rodents by Chaplan and colleagues (1994).  A recent 
literature survey found that in reports where von Frey filaments were used to assess 
mechanical sensitivity, over 60% used the up-down method or a modified up-down 
method to determine mechanical thresholds (Mills et al., 2012).  
 
Testing is conducted with a conventional set of eight different von Frey filaments.  These 
calibrated nylon monofilaments exert a reproducible vertical force level when pressed to 
the point of bending.  The series of filaments used in the up-down method have 
logarithmically incremental stiffness, as indicated by the handle markings, with ranges of 
0.41 – 15.14g in rats or 0.03 – 3.63g in mice (Table 4-2 and Figure 4-4).  The maximum 
stimulus intensity is subject to physical limitations, as with increasing stiffness filaments 
are more likely to raise the entire limb of the animal rather than buckle. 
 
For the up-down method, filaments are applied in sequential order starting at the middle 
of the series, with subsequent applications dependent on the prior response.  If there is 
no response, the stimulus force is increased by one step in filament size.  If a positive 
response (e.g. sharp withdrawal of the paw) is noted, the stimulus is decremented by 
one step.  Stimuli are presented at intervals of 30 seconds or longer to allow resolution 
of any previous response.  Testing is continued until six responses in the immediate 
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vicinity of the 50% withdrawal threshold are obtained or until the series is exhausted in 
either direction.  The 50% paw withdrawal threshold (PWT) is determined as: 
 
PWT = Χf + κδ 
 
where Χf is the value of the final von Frey filament employed (in log units), κ is the 
tabular Dixon value for the positive/negative pattern, and δ is the mean difference (in log 
units) between stimuli (Mills et al., 2012).  The threshold is converted from log units to 
gram units of force by: 
 
50% g threshold = (10(PWT))/10,000 
 
While a widely used method in pain research, the up-down method is not without faults.  
Depending on the particular pattern of positive and negative responses, the number of 
stimuli required for each animal will vary from four to nine per testing session, so all 
animals do not receive the same testing experience.  Particularly with large cohorts of 
animals, resolving lengthy positive/negative response patterns is time-consuming.  
Attention must also be paid to accurately tracking and recording the response pattern 
throughout the trial, and then correctly tabulating the response pattern from the Dixon 
values.  
 
To address these issues, Bonin and colleagues (2014) recently published a simplified 
up-down method (SUDO) for measuring mechanical sensitivity in rodents, which the 
authors posit is an efficient, user-friendly modification of the established up-down 
method.  Key differences are that a fixed number of five stimuli are used per trial and the 
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PWT is estimated from the filament value and response to the fifth stimulus without the 
use of the Dixon look-up table.  The authors allow that the proposed method lacks the 
precision in threshold calculation of the original up-down method, but suggest the 
simplified estimation should be sufficient. 
 
To validate and inform its future use, we critically evaluated the mathematical basis of 
the novel SUDO method.  Using archival mechanosensitivity measurements from mice 
and rats, we retrospectively compared the classical up-down method of Dixon/Chaplan 
to the SUDO method to determine whether the method produced usable PWT estimates. 
 
METHODS 
 
Retrospective von Frey data available for analysis included 512 measurements from rats 
(Sprague-Dawley, n = 36) and 1145 measurements from mice (C57BL/6 or congenic 
strains, n = 25; ICR, n = 49; mixed genetic background, n = 15).  Testing was performed 
by the same experimenter following standard procedures: animals were allowed to 
acclimate to the testing room within their home cages for at least 40 minutes before 
being placed individually within the testing apparatus, where they were given at least 20 
minutes to adjust to the testing environment.  Efforts were taken to minimize auditory, 
visual, and olfactory disturbances in the testing room.  The number of testing sessions 
per animal following baseline measurements ranged from 3 to 9 depending on the 
particular experimental design.  Tests were performed on nonconsecutive days, typically 
spaced seven days apart.  One response pattern was collected per animal at each 
testing session and was used to calculate the subject’s PWT. 
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Data were entered into a spreadsheet for analysis.  The PWT estimate was calculated 
from the response pattern using the methods described in Chaplan et al. or Bonin et al.  
Statistical tests performed included correlation, Bland-Altman method comparison, area 
under curve, one-way ANOVA with post-hoc Bonferroni’s multiple comparison test, and 
two-way repeated measures ANOVA with post-hoc Bonferroni’s multiple comparison test 
(GraphPad Prism version 5.0d, GraphPad Software, San Diego, California USA, 
www.graphpad.com).  A p value of < 0.05 was considered significant. 
 
RESULTS 
 
Response patterns.  The responses to sequential von Frey stimuli are recorded using 
the convention of X = withdrawal (positive) and O = no withdrawal (negative).  The 
resulting pattern is compared against Dixon’s lookup table of maximum likelihood 
estimates to determine the value of κ when calculating the PWT.  The pattern cannot 
exceed the stimulus set in either direction and optimally contains six values in the vicinity 
of the threshold.  If the initial response is positive (X), then this and the next five 
responses are considered the critical six values.  If the initial response is negative (O), 
the threshold must be crossed (OX) and then the next four responses will complete the 
six critical values.  Since the initial stimulus is in the middle of the series, the pattern 
length will vary from a minimum of four (XXXX, filaments 4-3-2-1) to a maximum of nine 
if the threshold is crossed at the seventh to the eighth filaments (such as in 
OOOOXOXOX, filaments 4-5-6-7-8-7-8-7-8). 
 
There are a finite number of patterns possible within the boundaries of this testing 
paradigm.  The lookup table in Chaplan et al. provides the tabular value for 250 
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positive/negative patterns.  However, this list includes pattern options that exceed the 
upper or lower extreme of the stimulus series as well as truncated patterns that do not 
contain six critical values.  For practical purposes, the up-down pattern list may be 
whittled down to 90 possible outcomes (Table 4-3). 
 
Unlike the up-down method, the SUDO method maintains a fixed number of stimulus 
applications, so the pattern length has a maximum of five.  Otherwise, testing 
progresses in a stepwise, sequential fashion according to the original method.  Thus the 
SUDO pattern list consists of 31 possible outcomes (Table 4-4).  Instead of using the 
tabular maximum likelihood estimate, an adjustment factor of ±0.5 is used, with the sign 
depending on the response to the fifth filament (positive for O and negative for X).  To 
further simplify the calculations, the filaments are assigned whole number values instead 
of using the filament handle marking, with the corresponding average step size set at 1. 
 
Correlation and agreement.  Given that each assay yields a discrete set of values and 
the SUDO pattern can be derived from the longer up-down pattern, the tests can be 
compared over the whole range of possible values without the need for real-world rodent 
data.  The PWT was calculated as shown above for the 90 up-down method patterns 
and the corresponding abridged SUDO patterns.  To maintain the same units between 
methods, filaments were designated as the whole numbers 1 through 8 in ascending 
order of stiffness, which also kept the mean difference between stimuli at 1.  The value 
of the adjustment factor κ was either the tabular Dixon value or ±0.5.  In keeping with the 
findings of Bonin et al., the PWT estimates derived from the SUDO method correlate 
well with those from Dixon/Chaplan (Pearson r = 0.942, p < 0.0001; Figure 4-5 A).  
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However, while this finding of strong correlation shows that the two variables are linearly 
related, it does not demonstrate how well the results of the two methods agree. 
 
Expanding on the findings of Bonin et al., we used the graphical method advocated by 
Bland and Altman (Bland and Altman, 1986) to plot the difference scores of the two 
measurements of PWT against the average of the two measurements in order to 
evaluate agreement (Figure 4-5 B).  The average discrepancy or bias between the 
methods was -0.05 filament steps and the 95% limits of agreement were -1.3 to 1.2.  
Thus the SUDO method tends to give a slightly lower PWT estimate but may be 1.3 
filament steps below or 1.2 filament steps above the PWT yielded by the Dixon/Chaplan 
method.  By the Bland and Altman approach, the smaller the range between the two 
limits, the better the agreement.     
 
The developers of the SUDO method advocated the constant adjustment factor of ±0.5 
as it rendered the pattern lookup table unnecessary and simplified the calculations for 
the PWT estimate.  The selection of the value 0.5 was based on the strength of 
correlation between the Dixon/Chaplan score and the resulting SUDO score.  We 
questioned whether a different constant adjustment factor would improve the agreement 
between the methods.  Using an iterative approach, the adjustment factor was varied in 
increments of 0.01 to determine the 95% limits of agreement.  The narrowest range in 
the limits of agreement was obtained with a value of ±0.59, with a bias of -0.04 filament 
steps and 95% limits of agreement of -1.31 to 1.23 (Figure 4-6).  However, the 
advantage of using this over of the conceptually simple value of 0.5 was negligible. 
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Given the lookup table in Chaplan et al. provides the tabular value for each of the 
positive/negative patterns in the SUDO outcome list, we next investigated whether using 
the corresponding maximum likelihood estimates instead of a constant adjustment factor 
would improve the agreement between the full pattern versus using a fixed number of 
stimuli.  Calculations were performed as before using whole number designations for 
filaments (Figure 4-7).  The PWT estimates derived from the modified SUDO method 
using the Dixon tabular values had slightly stronger correlation with the PWT estimates 
from Dixon/Chaplan (Pearson r = 0.954, p < 0.0001).  The bias between the methods 
was further from zero (-0.14 filament steps), but the 95% limits of agreement were 
improved to -1.2 to 1.0.  So even with using the tabular Dixon values, the five stimuli 
pattern promoted in the SUDO method tends to give a slightly lower PWT estimate and 
may be 1.2 filament steps below or 1.0 filament steps above the PWT yielded by the 
Dixon/Chaplan method.      
 
Despite several mathematical approaches, limiting the response pattern to five stimuli 
results in limits of agreement with the complete pattern of around one full filament step.  
In assessing agreement between methods, the question of how close the measurements 
need to be is based on clinical context and is not determined statistically.  If a difference 
of 1.0 to 1.3 filament steps in the estimated PWT does not meaningfully affect the 
interpretation of the results, then the SUDO method could be used as a replacement for 
the original method.   
 
Retrospective data analysis.  To frame the question within clinical context, we applied 
the SUDO method to mechanosensitivity measurements from rats and mice.  The 
original measurements were conducted following the Dixon/Chaplan method and were 
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obtained by the same experimenter from animals at baseline or with varying degrees of 
experimental hypersensitivity.  The resulting pooled data set was composed of 1657 
positive/negative patterns from 125 individual rats and mice.  All response patterns 
complied with the parameters of the Dixon/Chaplan method; accordingly, pattern length 
varied from four to nine.  The average number of stimuli per trial was 6.3 with a standard 
deviation of 1.7.  The total number of stimuli within the pattern set was 10,363.  Filament 
presentations exceeding the advocated SUDO pattern length of five accounted for 
21.3% of the total number of stimuli.  If the SUDO method provides a reasonable 
estimate of the PWT, the reduction in the needed number of stimuli as compared to the 
original up-down method should result in more efficient use of experimenter time, 
particularly with large cohorts of animals. 
 
The proponents of the SUDO method suggested that repeated testing could result in a 
change in responsiveness of the animal, and keeping the number of stimuli constant 
would help negate this potential confound.  To ascertain whether following the up-down 
method could result in a change in responsiveness, from the retrospective data pool we 
identified a subset of control animals without experimental hypersensitivity that were 
tested at consistent intervals.  The resulting subset was composed of 20 mice tested at 
baseline and then once weekly for three weeks (Figure 4-8).  The average PWT 
decreased over time with increasing variability (baseline = 7.85 ± 0.09; day 21 = 7.43 ± 
0.23; average ± SEM), although this trend was not statistically significant by one way 
ANOVA with post-hoc Bonferroni multiple comparison test (p = 0.20).  The average 
change in PWT over three weeks was less than one filament step.  From the limited data 
set, it was not clear if this threshold decay would progress with time, if the downward 
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drift in the control PWT would have significance in experimental context, or if animal 
responsiveness would be different if testing under the SUDO method.      
 
In the complete pool of positive/negative patterns, the 90 possible patterns within the 
Dixon/Chaplan paradigm were not represented with equal frequency.  Four patterns 
disproportionately accounted for 65.9% of the data set – XXXX, OOOOO, OOOOXOO, 
and OOOOXOXOX – and sixteen patterns were absent.  Given the disparity in pattern 
occurrence, we questioned if this would influence subsequent assessments of 
correlation and agreement.  The PWT estimates were calculated as above using whole 
number designations for the filaments and an adjustment factor of either the tabular 
Dixon value or ±0.5 (Figure 4-9).  The strength of the correlation between the 
Dixon/Chaplan and SUDO scores was improved (Pearson r = 0.980, p < 0.0001), similar 
to the findings of Bonin et al. when the SUDO method was used to reanalyze existing 
measurements.  The bias between the methods was further from zero (-0.19 filament 
steps), and the 95% limits of agreement were narrowed to -1.1 to 0.75.  However, this 
still implies a potential difference in the estimated PWT of up to a full filament step.     
 
To determine if the difference in the estimated PWT meaningfully affects the 
interpretation of the clinical results, we reanalyzed data within specific experiments.  For 
each cohort, PWT estimates were calculated separately following the Dixon/Chaplan 
and SUDO methods.  The final data were analyzed using two-way repeated measures 
ANOVA (time x treatment) with post-hoc Bonferroni multiple comparison test and by 
quantifying the area under the PWT curve (AUC) followed by one-way ANOVA.  The 
three experiments selected for evaluation included animals with profound experimental 
hypersensitivity, no appreciable hypersensitivity, and moderate, variable hypersensitivity 
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as compared to non-allodynic controls.  Two experiments utilized the murine spared 
nerve injury (SNI) model of peripheral neuropathic pain (Decosterd et al., 2000; Pertin et 
al., 2012), while the third experiment tested a potential hypersensitivity-inducing 
treatment in animals without nerve damage. 
 
The first experiment evaluated four treatment groups with SNI against a control sham-
operated group (n = 4 – 6).  According to the original Dixon/Chaplan analysis, the mean 
PWT was significantly decreased in all groups with nerve injury as compared to the 
sham-operated control group at all time points evaluated following surgery (p < 0.0001; 
Figure 4-10 A).  However, at no time post-operatively were the SNI groups statistically 
different from each other.  Depending on the experimental context, a single 
measurement derived from the repeated measures may be considered more biologically 
meaningful.  For hypersensitivity data, the most accessible is the AUC for each subject.  
Similar to the repeated measures analysis, the average AUC was significantly 
decreased in all SNI groups as compared to the sham-operated control (p < 0.0001), 
while there was no statistical difference between SNI groups (Figure 4-10 C).   
 
We next performed all PWT calculations from the experimental data following the SUDO 
method to test whether levels of significance were changed.  A slight upward shift was 
apparent in the PWT curves for all groups (Figure 4-10 B), which was also evident as 
increases in the calculated AUC means (Figure 4-10 C).  However, the statistical 
relationships were consistent with the original analyses; reanalysis by the SUDO method 
did not cause statistical significance to be altered. 
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The second experiment evaluated two experimental treatments in animals without nerve 
injury compared to untreated controls (n = 7 – 8).  Unlike the first experiment, no 
hypersensitivity was evident in either treatment group by either repeated-measures 
testing or by AUC analysis (Figure 4-11 A, C).  Reanalysis by the SUDO method yielded 
observable variability in the PWT curves, but any differences between the groups 
remained non-statistically significant (Figure 4-11 B, C). 
 
Given that the SUDO method resulted in no meaningful difference in interpretation at 
clinical extremes, we next questioned whether the same could be said for data in the 
middle of the PWT range.  The third experiment evaluated two variations of the spared 
nerve injury surgery as compared to sham-operated controls in which recovery was 
expected in one of the injured groups (n = 6 – 9).  The PWT of one surgical group was 
significantly decreased at all later time points, but only temporarily for the second 
surgical group (Figure 4-12 A).  While perhaps less informative in this setting, the 
average AUC for both nerve-injured groups was also significantly decreased compared 
to sham-operated subjects (Figure 4-12 C).  When reanalyzed by the SUDO method, 
statistical significance was not lost, but the strength of the evidence was diminished as 
indicated by larger p values (Figure 4-12 B, C).   
 
DISCUSSION 
 
We questioned the reliability of the recently proposed SUDO method for 
mechanosensitivity measurements in rodents.  Our analysis generally supports the 
findings of Bonin and colleagues and expands upon the limitations of the testing method.  
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The only statistical comparison between the new and old techniques provided in the 
original report was the correlation coefficient.  The use of the correlation coefficient for 
this type of comparison is misleading, as it measures the relationship between the 
values but not the agreement (Bland and Altman, 1986).  For example, if the SUDO 
method always produced PWT estimates twice as big as the Dixon/Chaplan method, the 
PWT values would be highly correlated but would not agree.  We wanted to know if the 
difference in the duplicate measurements was trivial, in which case the methods could 
be used interchangeably, or serious enough to preclude the meaningful interpretation of 
the results.  Using Bland-Altman method comparison, we found the PWT estimate 
yielded by the SUDO method may be up to 1.3 filament steps above or below the 
Dixon/Chaplan PWT estimate.  From clinical experience with neuropathic pain models, 
nerve injury typically produces tactile allodynia characterized by PWT estimates falling 
below the 50% point of the filament series, while the PWT estimates from non-injured 
controls stay within the stiffest three filaments of the series.  In these cases, the disparity 
between hypersensitive and non-hypersensitive values should be sufficient to excuse 
the lack of precision from the SUDO method, which was evident from our retrospective 
data analysis.  However, if more subtle variations in tactile sensitivity are being 
investigated, the potential difference of a full filament step in the final measurement may 
warrant following the Dixon/Chaplan method instead of the abridged method. 
 
Another modification to streamline PWT estimate calculations was the use of a constant 
adjustment of ±0.5.  While we explored other adjustment factors, including other 
constants between 0 and 1 as well as values from the Dixon look-up table, no 
substantial improvements in the final values were appreciated.  The value of 0.5 is 
conceptually simple and facilitates easy mathematical derivations, particularly when 
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using whole number designations for the filaments and a filament step difference of 1.0.  
We elected to continue to use this adjustment factor in subsequent calculations due to 
the ease of use. 
 
When examining archival von Frey measurements from rodents with varying levels of 
hypersensitivity, it was noted that response patterns did not occur with equal frequency.  
Patterns that did not occur within the data set tended to either represent the middle of 
the filament series (PWT estimates at filaments 3 – 5) or complete reversals in 
response, such as OOOOXXXXX.  The patterns with the highest frequency were either 
near or at the maximum extreme of the series or the minimum extreme of the series.  
The most common cause of experimental hypersensitivity in the data set was 
standardized surgical nerve injury, which typically results in robust tactile allodynia.  
Given the inclusion of non-allodynic control animals, it is not surprising that 
measurements most often reflected either a high “normal” threshold or very low allodynic 
threshold, skirting the middle of the range.  Other models of experimental 
hypersensitivity may better encompass the full range of possible PWT values.  It seems 
likely that the experimental model may have more to do with pattern occurrence than the 
experience of the examiner, which contradicts the implication of Bonin et al.  However, 
clarification of this issue would require further studies.   
 
Another proposed advantage of the SUDO method is efficient use of experimenter time.  
Limiting the total number of stimuli recorded in the retrospective measurements to five 
would have resulted in 21.3% fewer filament presentations.  If using a rough estimate of 
30 seconds of experimenter time per filament presentation, generation of all the 
response patterns in the pooled retrospective data set required approximately 86 hours 
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of experimenter time, or an average of 3.12 minutes per pattern, which the SUDO 
method would have reduced to 68 hours or 2.46 average minutes per pattern.  The 
standardized number of filament presentations would also influence the length of time 
animals spend within the testing apparatus, as removal of animals from their individual 
enclosures can be disruptive.  All subjects remain on the testing apparatus until 
complete response patterns are obtained for the entire cohort.  Using the same rough 
time estimate, twenty animals all representing the extremes of pattern length would take 
anywhere from 40 to 90 minutes to generate a complete response pattern for each 
subject.  The SUDO method would limit this time to 50 minutes.  Standardizing the time 
animals spent within the testing enclosures would eliminate a potential source of bias, 
particularly if animals within an experiment needed to be tested in batches due to space 
limitations in the testing area. 
 
Prolonged testing sessions and variability in the number of stimuli have been identified 
as confounds that may result in a change in animal responsiveness over time (Chaplan 
et al., 1994).  While unable to explore whether threshold decay is more or less evident in 
animals tested by the SUDO method, we attempted to determine whether changing 
thresholds were apparent in animals tested by the Dixon/Chaplan method.  While limited 
by the number of animals that met the inclusion criteria, analysis did reveal a slight 
downward trend in the PWT that was not statistically significant.  It would be interesting 
to determine if a constant number of filament presentations, fixed time in the testing 
apparatus, or both reduced intra-subject variability in PWT estimates over time.  
 
An alternative method for measuring tactile sensitivity not addressed in the discussion of 
the SUDO method is to use an electronic von Frey apparatus instead of von Frey 
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filaments (Cunha et al., 2004; Martinov et al., 2013).  An electronic anesthesiometer 
consists of a hand-held pressure meter fitted with a polypropylene tip of uniform 
diameter and suitable rigidity for the species being tested.  The probe tip is applied with 
increasing force and measures the force when the paw is withdrawn.  The experimental 
withdrawal threshold is typically calculated from the average of three such 
measurements.  Advantages of electronic von Frey over classical filaments include not 
needing to switch between filament sizes during testing, fewer stimuli needed per trial, 
and availability of measurements outside the range physically allowed by filaments.  In 
practice, electronic von Frey should provide the same improvements to stimuli 
presentation, time consumption, and mathematical complexity as the SUDO method 
without necessarily sacrificing precision in the threshold calculations. 
 
However, electronic von Frey is not without disadvantages (as discussed in Chapter 2).  
The experimenter learning curve is steep and sufficient training is necessary to reach 
internal consistency in the application of probe force.  The equipment must be 
appropriate for the species being tested and the electronic device requires prior 
calibration and consistent maintenance.  The initial cost for the equipment is also 
considerably higher than for classical filaments: a recent price quote showed a 7-fold 
higher investment for an electronic von Frey anesthesiometer versus a standard 20-
filament kit ($2,995.00 and $426.00, respectively; Stoelting Co., Wood Dale, Illinois USA, 
www.stoeltingco.com).  To our knowledge, no studies are available investigating the 
agreement in rodent PWT estimates between electronic von Frey and either the 
Dixon/Chaplan up-down method or the SUDO method. 
 
CONCLUSIONS 
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The SUDO method for mechanosensitivity testing using von Frey filaments provides a 
reasonable alternative to the Dixon/Chaplan up-down method, although some degree of 
precision is sacrificed for time efficiency and user-friendliness.  The method appears 
best suited to experiments where robust hypersensitivity is expected and larger cohorts 
of animals require testing; the limits of agreement may be too broad for studies 
anticipating more subtle differences.  Standard methods for electronic von Frey usage 
provide many of the same advantages, but the necessary equipment and expertise may 
not be as readily available.  Further testing is required to determine whether the SUDO 
method reduces intra-subject variability and threshold decay over serial trials.   
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FIGURES 
 
 
 Rats  Mice 
Filament Handle marking Force (g)  Handle marking Force (g) 
1 3.61 0.4  2.44 0.04 
2 3.84 0.6  2.83 0.07 
3 4.08 1.0  3.22 0.16 
4 4.31 2.0  3.61 0.4 
5 4.56 4.0  3.84 0.6 
6 4.74 6.0  4.08 1.0 
7 4.93 8.0  4.31 2.0 
8 5.18 15.0  4.56 4.0 
 
 
 
Table 4-2, Standard von Frey filament series for rats and mice.  Traditionally, the handle 
marking is related to the bending force of the filament, calculated by Log10 of (10 x force 
in milligrams). 
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Figure 4-4, The series of filaments used in the up-down method have logarithmically 
incremental stiffness.  The bending forces for the rat and mouse series are shown using 
a logarithmic scale (A, C) and a linear scale (B, D). 
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Pattern Value for κ Pattern Value for κ Pattern Value for κ 
OOOOO  0.000  OOXOOOX -1.247  OXXXXX 0.893  
OOOOXOO  0.315  OOXOOXO  0.380  XOOOOO -0.893  
OOOOXOXOO  0.040  OOXOOXX -0.144  XOOOOX -1.603  
OOOOXOXOX -0.453  OOXOXOO  0.039  XOOOXO 0.043  
OOOOXOXXO  1.248  OOXOXOX -0.458  XOOOXX -0.500  
OOOOXOXXX  0.758  OOXOXXO 1.237  XOOXOO -0.296  
OOOOXXOOO -0.263  OOXOXXX 0.732  XOOXOX -0.831  
OOOOXXOOX -0.752  OOXXOOO -0.266  XOOXXO 0.831  
OOOOXXOXO  0.954  OOXXOOX -0.763  XOOXXX 0.296  
OOOOXXOXX  0.504  OOXXOXO 0.935  XOXOOO -0.611  
OOOOXXXOO  0.681  OOXXOXX 0.463  XOXOOX -1.169  
OOOOXXXOX  0.252  OOXXXOO 0.648  XOXOXO 0.500  
OOOOXXXXO  2.014  OOXXXOX 0.187  XOXOXX -0.022  
OOOOXXXXX  1.496  OOXXXXO 1.917  XOXXOO 0.169  
OOOXOOO -0.154  OOXXXXX 1.329  XOXXOX -0.372  
OOOXOOXO  0.381  OXOOOO -0.547  XOXXXO 1.250  
OOOXOOXX -0.142  OXOOOX -1.250  XOXXXX 0.547  
OOOXOXOO  0.040  OXOOXO 0.372  XXOOOO -0.897  
OOOXOXOX -0.453  OXOOXX -0.169  XXOOOX -1.500  
OOOXOXXO  1.247  OXOXOO 0.022  XXOOXO 0.169  
OOOXOXXX  0.756  OXOXOX -0.500  XXOOXX -0.372  
OOOXXOOO -0.263  OXOXXO 1.169  XXOXOO -0.169  
OOOXXOOX -0.753  OXOXXX 0.611  XXOXOX -0.737  
OOOXXOXO  0.952  OXXOOO -0.296  XXOXXO 0.861  
OOOXXOXX  0.500  OXXOOX -0.831  XXOXXX 0.154  
OOOXXXOO  0.678  OXXOXO 0.831  XXXOOO -0.500  
OOOXXXOX  0.244  OXXOXX 0.296  XXXOOX -1.139  
OOOXXXXO  2.000  OXXXOO 0.500  XXXOXO 0.432  
OOOXXXXX  1.465  OXXXOX -0.043  XXXOXX -0.315  
OOXOOOO -0.547  OXXXXO 1.603  XXXX -1.000  
         
 
 
Table 4-3, The 90 relevant outcomes in Dixon’s lookup table of maximum likelihood 
estimates. 
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Pattern Value for κ Pattern Value for κ 
OOOOO 0.5  XOOOO 0.5  
OOOOX -0.5  XOOOX -0.5  
OOOXO 0.5  XOOXO 0.5  
OOOXX -0.5  XOOXX -0.5  
OOXOO 0.5  XOXOO 0.5  
OOXOX -0.5  XOXOX -0.5  
OOXXO 0.5  XOXXO 0.5  
OOXXX -0.5  XOXXX -0.5  
OXOOO 0.5  XXOOO 0.5  
OXOOX -0.5  XXOOX -0.5  
OXOXO 0.5  XXOXO 0.5  
OXOXX -0.5  XXOXX -0.5  
OXXOO 0.5  XXXOO 0.5  
OXXOX -0.5  XXXOX -0.5  
OXXXO 0.5  XXXX -0.5  
OXXXX -0.5     
      
 
 
Table 4-4, The 31 possible outcomes and adjustment factors in the SUDO method. 
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Figure 4-5, Analysis of the ninety potential outcome values of the Dixon/Chaplan up-
down method and the corresponding SUDO value (using an adjustment factor of ±0.5).  
(A) The outcome values of the Dixon/Chaplan up-down method and the corresponding 
calculated SUDO value, shown with a line of equality.  The two methods demonstrate 
strong correlation (Pearson r = 0.942, p < 0.0001).  (B) Bland-Altman plot of the same 
set of discrete values.  The solid grey line represents the average discrepancy or bias (-
0.05 filament steps) and the dashed grey greys represent the 95% limits of agreement 
(two standard deviations above or below the mean).  The SUDO method tends to give a 
slightly lower PWT estimate but may be 1.3 filament steps below or 1.2 filament steps 
above the PWT yielded by the Dixon/Chaplan method.    
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Figure 4-6, By the Bland and Altman approach, the smaller the range between the two 
limits (dashed lines), the better the agreement.  Iteratively varying the SUDO adjustment 
factor in increments of 0.01 revealed the narrowest range in the limits of agreement 
between the Dixon/Chaplan and SUDO methods was obtained with a value of ±0.59.  
The advantage of this value over the conceptually simple value of 0.5 was negligible. 
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Figure 4-7, Analysis of the ninety potential outcome values of the Dixon/Chaplan up-
down method and the corresponding SUDO value (using the tabular adjustment factor).  
(A) Using the corresponding tabular Dixon maximum likelihood estimates rather than the 
constant SUDO adjustment factor improved the strength of correlation (Pearson r = 
0.954, p < 0.0001); shown with line of equality.  (B) Bland-Altman analysis revealed bias 
further from zero (-0.14 filament steps) and similar 95% limits of agreement (-1.2 to 1.0 
filament steps) to use of the constant adjustment factor.   
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Figure 4-8, PWT values obtained by the Dixon/Chaplan method from 20 control mice 
pooled from several experiments.  The average PWT decreased and became more 
variable over time, although this trend was not significant.  The primary and secondary 
axes show the whole number score and equivalent filament force value.    
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Figure 4-9, Correlation (A) and Bland-Altman analysis (B) of retrospective PWT data 
from rats and mice.  The possible response patterns were not represented with equal 
frequency, resulting in stronger correlation (Pearson r = 0.980, p < 0.0001).  The bias 
between the methods was further from zero (-0.19 filament steps), and the 95% limits of 
agreement were narrowed to -1.1 to 0.75.  However, this still implies a potential 
difference in the estimated PWT of up to a full filament step.     
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Figure 4-10, (A) By the original Dixon/Chaplan analysis, the mean PWT was 
significantly decreased in all SNI groups at all time points following surgery (p < 0.0001). 
The vertical dotted lines at day 0 and day 32 indicate the day of surgery and initiation of 
the experimental treatment, respectively.  The primary and secondary axes show the 
whole number score and equivalent filament force value.  (B) Converting the 
retrospective data to the SUDO method did not cause any statistical relationships to be 
altered.  (C) The average area under the PWT curve was significantly decreased in all 
SNI groups as compared to the sham-operated control group (p < 0.0001).  These 
relationships were changed following reanalysis by the SUDO method.     
 
 
 
	  160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11, PWT values in mice without nerve injury evaluating two experimental 
treatments compared to saline-treated controls.  No hypersensitivity was evident in (A) 
the original Dixon/Chaplan analysis, (B) the SUDO reanalysis, or in (C) the area under 
the PWT curves. 
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Figure 4-12, PWT values in mice with standard SNI (transection and ligation) and SNI in 
which the nerve was crushed and allowed to regenerate.  (A) By the original 
Dixon/Chaplan analysis, the PWT was significantly decreased as composed to sham-
operated controls at post-operative days 14, 21, and 28.  In the nerve recovery group, 
the PWT was significantly decreased at post-operative days 7 and 14, but then returned 
to baseline.  (B) With reanalysis of the converted SUDO values, statistical relationships 
were maintained, but the p values tended to be larger.  (C) The area under PWT curve 
was significantly decreased compared to sham-operated controls in both SNI groups.  
Reanalysis with the SUDO method resulted in diminished p values (* p < 0.05, ** p < 
0.01, *** p < 0.001, # p < 0.0001). 
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Chapter 5 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theory is when you know everything but nothing works.  Practice is when everything 
works but no one knows why.  In our lab, theory and practice are combined: nothing 
works and no one knows why. 
– Anonymous 
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The purpose of this research was to investigate the functional role of VGF-derived 
peptides in sensory neuron signaling and in the development of somatic and visceral 
pain-relevant behavior. 
 
VGF was initially identified as a nerve growth factor-inducible transcript in PC12 cells by 
Levi and colleagues in 1985, with the accepted non-acronymic name deriving from 
culture plate V and nerve growth factor (Salton et al., 2000).  Biological activities have 
since been described for a number of VGF-derived peptides.  However, the challenge 
confronting investigators of VGF, as with other granins, is the paucity of information 
available on specific signaling pathways, cognate receptors, or cellular mechanisms of 
action (Bartolomucci et al., 2011).  While daunting, these gaps in knowledge 
nonetheless provide opportunities for discovery, and there is increasing interest in the 
utility of granin-derived peptides in therapeutic intervention or as biomarkers of disease.   
 
To further characterize the VGF signaling system in primary afferent neurons, we utilized 
animal models of viral-mediated gene transfer and antibiotic-induced visceral 
hypersensitivity.  From this work, we learned intrasciatic administration of AAV5 (driving 
either GFP or VGF) yields predominately local transduction with inefficient and variable 
transduction of sensory and motor neurons, reminiscent of the AAV8 serotype and unlike 
AAV1, AAV2, and AAV6.  Intrathecal administration of AAV5-VGF by direct lumbar 
puncture resulted in successful transduction of the choroid plexus in the fourth ventricle 
but poor expression in DRG sensory neurons.  Antibiotic treatment and presumed 
dysbiosis were associated with up-regulation of VGF, as well as CGRP and SP, in small-
diameter sensory neurons of the sixth lumbar DRG.  Contrary to expectations, referred 
cutaneous allodynia associated with antibiotic-induced visceral hypersensitivity was not 
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readily detected using a non-invasive mechanical stimulation assay.  Collectively, these 
findings encourage a re-evaluation of the tools employed to modulate VGF expression in 
primary afferent neurons in vivo while supporting the investigation of this novel signaling 
system beyond models of nerve injury. 
 
Intrasciatic AAV5.  We attempted to limit viral-mediated gene expression to primary 
sensory neurons by employing a specific route of administration.  This method of 
transductional targeting was not successful, as we learned AAV5 demonstrates 
differential tropism following intraneural injection.  It should be possible to restrict viral-
mediated gene delivery to sensory neurons through intraneural delivery using a different 
AAV serotype that maintains neurotropism.  However, a less-invasive administration 
method seems preferable, as iatrogenic neuron damage is an undesirable sequela of 
direct injection into peripheral nervous tissue.  
 
An alternative approach would be to utilize transcriptional targeting to limit vector gene 
expression to specific cells.  The promoter is the gene regulatory element that drives 
transcription and determines the strength and cell-type specificity of expression.  For 
AAV vectors, the use of promoters that restrict gene expression to defined cellular 
subtypes is hampered by the small packaging capacity (up to 4.7 kb) and the typically 
large size of mammalian promoters (tens to hundreds of kilobases) (Dong et al., 1996; 
Betley and Sternson, 2011).  Several compact, neuron-specific promoters have been 
developed and demonstrated to be AAV-compatible, including the neuron-specific 
enolase promoter (Peel et al., 1997) and human synapsin 1 gene promoter (Kügler et 
al., 2003).  However, limiting vector-mediated gene expression to neurons would not 
resolve the issue of off-target transduction of neurons in the central nervous system.   
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A promising candidate for genetic manipulation of primary sensory neurons is the 
Advillin gene.  Advillin encodes a protein in the actin binding family and is expressed 
almost exclusively in peripheral sensory neurons (Hasegawa et al., 2007).  Using the 
upstream putative regulatory sequence of the gene, Zuborg and colleagues (2011) were 
able to develop a transgenic mouse line that expresses Cre-recombinase (Cre) 
exclusive to peripheral sensory neurons.  To date, the particular sequence of the Advillin 
promoter has not been determined, and the large upstream promoter regulatory region 
used to generate the transgenic mouse line far exceeds the capacity of an AAV vector 
(168 kb).  It is not currently possible to construct a sensory neuron-specific AAV vector.   
 
To overcome these problems, a combined approach utilizing transgenic animals and 
AAV vectors may be warranted.  Genetic modification of the mouse genome can take 
advantage of cell type-specific promoters that are too large to be accommodated by the 
AAV genome.  Cre-dependent expression vectors utilize a strong, ubiquitous promoter 
but the activity is limited to cells selectively expressing Cre.  Standard methods to 
generate the Cre-dependent vector construct include placing a stop cassette flanked by 
two loxP sites between the promoter and the transgene.  Cre activates the transgene by 
excising the stop cassette.  Unfortunately, stop cassettes occupy a substantial portion of 
the packaging capacity (1 to 2 kb), and “read-through” transcription is possible (Betley 
and Sternson, 2011).  A strategy better adapted to AAV vectors is a flip-excision (FLEX) 
switch, which utilizes two pairs of heterotypic loxP sites and inversion of the transgene 
with respect to the promoter.  In the presence of Cre, FLEX recombination changes the 
orientation of the coding sequence from anti-sense to sense.  The FLEX switch is tightly 
regulated, highly efficient, and compact (0.30 kb) (Atasoy et al., 2008).   
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With respect to conditional VGF overexpression in sensory neurons, the adapted 
approach would require access to the Advillin-Cre driver mouse line and generation of a 
novel AAV vector construct.  Back-of-the-envelope calculations suggest that there 
should be sufficient packaging capacity for a typical ubiquitous promoter sequence (~ 
1000 bp, 22%), FLEX switch (~300 bp, 7%), and the VGF coding sequence (~1850 bp, 
41%).  The ideal serotype would demonstrate robust sensory neurotropism following 
intrathecal delivery, as has been described for AAV9 (Schuster et al., 2014b).  Despite 
transport of the virus within the cerebrospinal fluid to distant, off-target sites, viral-
mediated expression of the gene of interest would be selective to primary sensory 
neurons expressing Cre.  However, the feasibility of this proposed approach is uncertain, 
as Advillin-Cre mice are not yet commercially available in the United States (The 
Jackson Laboratory, www.jax.org). 
 
AAV9-induced sensory neuronopathy.  While a useful tool, viral-mediated gene 
transfer to sensory neurons is not without risk.  We provided evidence of unexpected 
and variable sensory neuron degeneration associated with robust sensory neurotropism 
and exuberant fluorescent reporter gene expression mediated by AAV9 vectors.  
Unfortunately, the pathobiological consequences of this unexpected sensory 
neuronopathy remain unclear, as no behavioral outcome measures were available from 
the affected animals and the overall extent of neuron loss could not be quantified. 
 
A late revelation was the observation of GFP expression in putative satellite glial cells 
(SGCs).  In the DRG, each sensory neuron soma is individually surrounded by a 
continuous envelope of multiple SGCs (Hanani, 2005).  This complete ensheathment is 
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anatomically unique and not found in glial-neuron associations in the central nervous 
system.  While long considered to merely give mechanical support, increasing evidence 
suggests that SGCs interact with neurons and have many essential functions, including 
controlling the extracellular microenvironment, receiving and transmitting chemical 
signals, and acting as the tissue-resident antigen presenting cells (Hanani, 2005; van 
Velzen et al., 2009).   
 
SGCs may be distinguished from neurons immunohistochemically.  The most useful 
marker is glutamine synthetase; glial fibrillary acidic protein is also expressed in 
activated cells, but may be negligible in resting SGCs.  Specific staining for SGCs is not 
consistently described in reports evaluating AAV transduction of sensory ganglia.  In the 
limited studies that include the satellite glia, no transduction of SGCs was evident with 
AAV6 (Towne et al., 2009; Yu et al., 2013).  However, occasional expression of GFP 
was observed in SGCs transduced by AAV8 (Fischer et al., 2011).  Transduction of glia-
like cells in the DRG with crescentic morphology consistent with SGCs was reported in 
nonhuman primates treated with AAV7 and AAV9, but these cells were not characterized 
further (Samaranch et al., 2013).   
 
The significance of unintentional SGC transduction may warrant further consideration.  
In this report, it seems likely that expression of a foreign protein in these antigen 
presenting cells elicited a destructive cellular immune response in certain animals.  
Additionally, the intricacies of the bidirectional communication between neuronal somata 
and SGCs are not well understood.  With regards to viral-mediated expression of VGF, 
induced release of VGF-derived peptides by SGCs may not trigger the same signaling 
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pathways as endogenously produced VGF in sensory neurons, potentially leading to 
spurious, confusing results. 
 
Pain-relevant behavior.  Perplexity was already amply apparent with the mechanical 
stimulation assay used to non-invasively monitor putative antibiotic-induced visceral 
hypersensitivity.  While some variability in response rates could be explained through 
differing states of dysbiosis, the absence of referred cutaneous allodynia following 
intracolonic instillation of capsaicin was particularly troubling.  Meanwhile, the up-
regulation of nociceptive neuropeptides in predominantly small-diameter primary afferent 
neurons in relevant DRG was consistent with increased pain signaling, despite the 
behavior assays only sporadically identifying a hypersensitive phenotype.       
 
However, it could be argued that assays of mechanical allodynia and thermal sensitivity, 
as employed throughout these projects, are only measuring nociceptive reflexes and not 
what would be considered “pain” in the human experience.  Spontaneous pain, arguably 
the most important human clinical symptom, cannot be objectively measured in rodents, 
and this has led to conflict in the field over the validity and translational value of rodent 
models (Mogil, 2009; Barrot, 2012).  The challenge is that pain is a conscious, 
subjective, and emotional experience that is assessed by verbal expression, which is not 
possible in animal models.  Additionally, rodents are prey species and are therefore 
motivated to not display disability to predators or conspecifics.   
 
Recent work adapting tools developed in other fields of behavioral neuroscience has 
suggested that changes in emotional wellbeing can be objectively quantified in rodent 
pain.  Decreased willingness to participate in spontaneous, rewarding behavior – such 
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as nest building, digging tasks like burrowing, or ad libitum consumption of sucrose 
solution – has been interpreted to represent an altered emotional state consistent with 
pain in several rodent models (Jirkof et al., 2010; Strekalova and Steinbusch, 2010; 
Yalcin et al., 2011; Andrews et al., 2012; Bura et al., 2013).  However, incorporation of 
such assays must be planned judiciously.  For, just as apparent negative changes in the 
global emotional state of the animal resulted in aberrantly decreased thresholds to 
mechanical stimuli (discussed in Chapter 2), the provision of enrichment materials has 
been shown to attenuate nerve-injury induced hypersensitivity to mechanical and 
thermal stimuli (Vachon et al., 2013).     
 
Up-regulation of VGF after intestinal dysbiosis.  Nociceptive sensory neurons are 
commonly classified by their neurochemical signatures.  In the mouse, peptidergic 
nociceptors are demarcated from non-peptidergic by the expression of CGRP and/or SP, 
TRPV1, and the TrkA receptor, while non-peptidergic nociceptors bind IB4 and express 
the P2X3 receptor (Price and Flores, 2007).  In DRG culture and in models of 
neuropathic pain, up-regulated VGF in sensory neurons has been shown to co-localize 
with SP, CGRP, TrkA, and P2X3 (Rizzi et al., 2008; Riedl et al., 2009), suggesting that 
VGF induction is not restricted to a particular subset of sensory neurons.   
 
As evidenced in our pilot work investigating a murine model of visceral hypersensitivity, 
up-regulation of VGF occurred in sensory neurons of varying size and neurochemistry, 
reminiscent of the previous findings in rats following nerve injury (Riedl et al., 2009).  
Only one time point was evaluated, with animal sacrifice and tissue collection occurring 
on the day after antibiotic treatment was completed.  It is not clear whether this coincides 
with the peak of presumed visceral hypersensitivity, given the variability in behavioral 
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outcomes, for how long this increased expression would persist, or whether the up-
regulation could be modulated by probiotic therapy.  It should be noted, however, that 
further investigation of VGF expression in visceral pain would benefit from the use of a 
standardized model with a more robust, reliable behavioral phenotype.  
 
Immunohistochemical analysis was pragmatically limited to the L6 DRG.  However, as 
demonstrated by Robinson and colleagues (2004), the descending colon of the mouse 
receives sensory innervation from thoracolumbar DRG as well.  Given the T8-L1 DRG 
also innervate the dermatomes of the ventral abdomen, involvement of nociceptive 
neurons from these segments may bear stronger correlation to the presence or absence 
of referred cutaneous allodynia.  Provided an appropriate behavioral assay is identified 
to non-invasively monitor animals for referred hypersensitivity, investigation of DRG from 
this segment may be informative. 
 
CONCLUSIONS 
 
To further characterize the functional role of VGF-derived peptides in sensory neuron 
signaling and in the development of pain-relevant behavior, we utilized animal models, 
behavior analyses, and complementary morphologic and molecular techniques to pursue 
two approaches: using AAV vectors to modulate VGF expression in primary afferent 
neurons in vivo, and exploring whether VGF up-regulation is limited to somatic pain.   
 
Unfortunately, we learned that AAV5-VGF, delivered intraneurally or intrathecally, was 
not a useful tool for investigating behavior outcomes of sensory neuron overexpression 
of VGF.  We also witnessed sensory neuron degeneration and loss induced by AAV9, 
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raising some concerns regarding the use of this AAV serotype in DRG.  Antibiotic-
induced dysbiosis and presumed visceral hypersensitivity were associated with VGF up-
regulation in DRG sensory neurons in a pattern similar to that seen in nerve injury, 
suggesting VGF also plays a functional role in visceral pain, but a reliable behavioral 
phenotype could not be established.       
 
Collectively, these findings encourage a re-evaluation of the tools employed to modulate 
VGF expression in primary afferent neurons in vivo, support the investigation of this 
novel signaling system beyond models of nerve injury, and are presented such that they 
can be used as an aid in the design of future work.   
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